[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 162
1. Niimi Y, Kawana S: Type 2 segmental manifestation of disseminated superficial actinic porokeratosis in a 7-year-old girl. Eur J Dermatol; 2009 Jan-Feb;19(1):25-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type 2 segmental manifestation of disseminated superficial actinic porokeratosis in a 7-year-old girl.
  • We report here a rare case of porokeratosis in which two different clinical types of porokeratosis (linear porokeratosis and disseminated superficial actinic porokeratosis) coexisted.
  • A 7-year-old girl developed a centrifugal lesion on her left abdomen at the age of 2, disseminated superficial actinic porokeratosis on her face at the age of 3 after ultraviolet exposure, and linear porokeratosis on her left body at the age of 5.
  • We consider that this case may represent a type 2 segmental manifestation of disseminated superficial actinic porokeratosis.

  • Genetic Alliance. consumer health - Porokeratosis, disseminated superficial actinic 2.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19059828.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Dermatologic Agents; 103909-75-7 / maxacalcitol; FXC9231JVH / Calcitriol
  • [Number-of-references] 39
  •  go-up   go-down


2. Shoimer I, Rosen N, Muhn C: Current management of actinic keratoses. Skin Therapy Lett; 2010 May;15(5):5-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of actinic keratoses.
  • An actinic keratosis (AK) is a pre-malignant cutaneous lesion that frequently manifests in sun-exposed areas of the skin as a small, rough, scaly erythematous papule.
  • [MeSH-major] Carcinoma, Squamous Cell / prevention & control. Keratosis, Actinic / therapy. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505896.001).
  • [ISSN] 1201-5989
  • [Journal-full-title] Skin therapy letter
  • [ISO-abbreviation] Skin Therapy Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 144O8QL0L1 / Diclofenac; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Ulrich C, Forschner T, Ulrich M, Stockfleth E, Sterry W, Termeer C: Management of actinic cheilitis using diclofenac 3% gel: a report of six cases. Br J Dermatol; 2007 May;156 Suppl 3:43-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of actinic cheilitis using diclofenac 3% gel: a report of six cases.
  • BACKGROUND: Actinic cheilitis is a frequent manifestation of actinic dysplasia and requires early therapy to prevent its progression into invasive squamous cell carcinoma (SCC).
  • Several therapies are used, ranging from unspecific lesion-adapted destructive techniques (i.e. laser) to ambitious surgical field-management (vermillionectomy).
  • Diclofenac 3% gel is used in the treatment of actinic keratosis (AK), but it has not been evaluated for the treatment of actinic cheilitis.
  • OBJECTIVES: This non-blinded, uncontrolled case series study evaluated the effects of diclofenac 3% gel in the treatment of actinic cheilitis.
  • PATIENTS/METHODS: Six patients with histologically verified actinic cheilitis were treated with diclofenac 3% gel, twice daily for 6 weeks.
  • RESULTS: Four out of six patients showed clinical clearing of actinic cheilitis 2-4 weeks after the end of treatment.
  • CONCLUSIONS: Topical therapy with diclofenac 3% gel may be an efficient, cosmetically more appealing alternative treatment for actinic cheilitis than currently used destructive therapies.

  • Genetic Alliance. consumer health - Actinic Cheilitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488406.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Gels; 144O8QL0L1 / Diclofenac
  •  go-up   go-down


Advertisement
4. Berlin JM, Rigel DS: Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol; 2008 Jul;7(7):669-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery.
  • BACKGROUND: Actinic keratoses are increasingly common skin lesions that are evaluated and treated by dermatologists on a daily basis.
  • It is estimated that more than 90% of actinic keratoses in the US are treated by destructive therapies, such as cryosurgery.
  • A total of 714 subjects who had a clinical diagnosis of actinic keratosis with between 5 and 15 lesions contained in a target area such as the forehead, scalp, and hands were enrolled in the study.
  • Lesion counts were assessed at baseline, and 45, 75, 105, and 135 days after cryosurgery.
  • At the conclusion of the study, 46% of the subjects in the cryosurgery followed by the use of diclofenac sodium 3% gel arm achieved 100% cumulative (target plus new lesions) lesion clearance compared to 21% in the cryosurgery alone arm (P < .0001).
  • One hundred percent target lesion clearance was achieved in 64% of the subjects in the active arm compared to 32% in the cryosurgery alone arm (P < .0001).
  • CONCLUSIONS: With the increased prevalence of actinic keratoses, it is important to consider and evaluate emerging therapeutic options.
  • The sequential treatment with cryosurgery followed by diclofenac sodium 3% gel for 90 days is well tolerated and can provide a therapeutic modality that may provide patients with actinic keratoses a more successful outcome than monotherapy with cryosurgery by effectively treating clinical and subclinical lesions.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18664159.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Gels; 144O8QL0L1 / Diclofenac
  •  go-up   go-down


5. Stough D, Bucko AD, Vamvakias G, Rafal ES, Davis SA: Fluorouracil cream 0.5% for the treatment of actinic keratoses on the face and anterior scalp: interim results of an 18-month open-label study. J Clin Aesthet Dermatol; 2008 Jul;1(2):16-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorouracil cream 0.5% for the treatment of actinic keratoses on the face and anterior scalp: interim results of an 18-month open-label study.
  • OBJECTIVE: This study further assessed the long-term safety and efficacy of fluorouracil cream 0.5% in patients with multiple actinic keratosis (AK) on the face/anterior scalp and other body sites.
  • At the end of Cycle 1, significant reductions were noted in lesion counts on the face/anterior scalp (84.8%; P<0.0001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21103318.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2989824
  •  go-up   go-down


6. Alotaibi L, Provost N, Gagnon S, Franco EL, Coutlée F: Diversity of cutaneous human papillomavirus types in individuals with and without skin lesion. J Clin Virol; 2006 Jun;36(2):133-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diversity of cutaneous human papillomavirus types in individuals with and without skin lesion.
  • RESULTS: Seventy-five (92.6%) of 81 subjects provided samples that could be analysed with PCR (34 healthy controls <50 years old, 13 healthy controls > or =50 years old, 12 with actinic keratosis (AK), 8 with squamous cell carcinoma (SCC) and 8 renal transplant recipients).

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16678481.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Viral
  •  go-up   go-down


7. Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA: Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol; 2006 Jul-Aug;16(4):335-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratosis: how to differentiate the good from the bad ones?
  • Our objective was to obtain practical clinical parameters to indicate those actinic keratoses (AK) that are at risk of becoming invasive.
  • Only 1 study (meta-analysis) examined the percentage of malignant transformation and found a rate between 0.025% and 20% per year/per lesion.
  • The amount of quality research on the most common premalignant lesion in humans is disappointing.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935787.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 44
  •  go-up   go-down


8. Dixon A: Rare skin cancers in general practice. Aust Fam Physician; 2007 Mar;36(3):141-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mr LA has long been troubled with actinic damage to his skin, especially his face.
  • On this occasion Mr LA had two actinic lesions on his left cheek that failed to respond to cryotherapy.
  • Histology of the superior lesion revealed sebaceous carcinoma.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339977.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


9. Huber MA: White oral lesions, actinic cheilitis, and leukoplakia: confusions in terminology and definition: facts and controversies. Clin Dermatol; 2010 May-Jun;28(3):262-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] White oral lesions, actinic cheilitis, and leukoplakia: confusions in terminology and definition: facts and controversies.
  • Although most encountered white oral lesions are innocuous, some potentially serious conditions may mimic an innocuous white lesion.
  • As examples, oral lichen planus may cause significant patient discomfort and is associated with some degree of increased malignant risk, whereas actinic cheilitis and leukoplakia have a confirmed association with an increased malignant risk.


10. Wennberg AM, Stenquist B, Stockfleth E, Keohane S, Lear JT, Jemec G, Mork C, Christensen E, Kapp A, Solvsten H, Talme T, Berne B, Forschner T: Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study. Transplantation; 2008 Aug 15;86(3):423-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This open randomized, intrapatient, comparative, multicenter study included 81 transplant recipients with 889 lesions (90% actinic keratoses (AK)].
  • The control, 50 cm2 area (n=413 lesions) received lesion-specific treatment (83% cryotherapy) at baseline and 3, 9, and 15 months.
  • Additionally, all visible lesions were given lesion-specific treatment 21 and 27 months in both treatment and control areas.

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698246.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


11. Warren CB, Lohser S, Wene LC, Pogue BW, Bailin PL, Maytin EV: Noninvasive fluorescence monitoring of protoporphyrin IX production and clinical outcomes in actinic keratoses following short-contact application of 5-aminolevulinate. J Biomed Opt; 2010 Sep-Oct;15(5):051607
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive fluorescence monitoring of protoporphyrin IX production and clinical outcomes in actinic keratoses following short-contact application of 5-aminolevulinate.
  • Topical 5-aminolevulinic acid (ALA) is widely used in photodynamic therapy (PDT) of actinic keratoses (AK), a type of premalignant skin lesion.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Keratosis, Actinic / drug therapy. Keratosis, Actinic / metabolism. Photochemotherapy / methods. Protoporphyrins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lasers Surg Med. 2000;26(1):76-82 [10637006.001]
  • [Cites] J Am Acad Dermatol. 2009 Dec;61(6):1033-43 [19925929.001]
  • [Cites] Br J Dermatol. 2001 May;144(5):983-90 [11359385.001]
  • [Cites] Acta Derm Venereol. 2001 Aug-Sep;81(4):246-9 [11720169.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):33-40 [14732657.001]
  • [Cites] Dermatol Surg. 2004 Jul;30(7):1054-61 [15209801.001]
  • [Cites] Br J Dermatol. 2006 Feb;154(2):305-9 [16433801.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1211-20 [16504761.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):5-14 [17126737.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):119-20 [17126750.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] Adv Dermatol. 2006;22:219-58 [17249304.001]
  • [Cites] Photochem Photobiol. 2007 May-Jun;83(3):738-48 [17576383.001]
  • [Cites] J Drugs Dermatol. 2007 Dec;6(12):1197-202 [18189059.001]
  • [Cites] J Drugs Dermatol. 2008 Nov;7(11):1033-7 [19110733.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3333-43 [19447864.001]
  • [Cites] Photochem Photobiol. 2000 Oct;72(4):569-74 [11045731.001]
  • (PMID = 21054081.001).
  • [ISSN] 1560-2281
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA084203
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  • [Other-IDs] NLM/ PMC2955723
  •  go-up   go-down


12. Uhlenhake EE, Sangueza OP, Lee AD, Jorizzo JL: Spreading pigmented actinic keratosis: a review. J Am Acad Dermatol; 2010 Sep;63(3):499-506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spreading pigmented actinic keratosis: a review.
  • INTRODUCTION: Spreading pigmented actinic keratosis (SPAK) is a common, but uncommonly reported or appreciated, variant of classic actinic keratosis (AK).
  • METHODS: A literature search was performed in both PubMed and MEDLINE databases using the search terms "spreading pigmented actinic keratosis," "pigmented solar keratosis," "pigmented actinic," and "pigmented solar."
  • RESULTS: SPAK is a rarely reported lesion that can be difficult to distinguish from other benign and malignant pigmented lesions, including seborrheic keratosis, melanoma in situ (lentigo maligna type), and lentigo maligna melanoma.
  • Located mainly on sun-exposed areas and with a size greater than 1.5 cm, the lesion typically spreads laterally.
  • Pathologically, the lesion resembles classic AK with increased basal melanization.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Hutchinson's Melanotic Freckle / pathology. Keratosis, Actinic / pathology. Precancerous Conditions / pathology. Skin Neoplasms / pathology


13. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM: Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer; 2009 Jan;7(1):20-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
  • Cutaneous squamous cell carcinoma (SCC) and inflammation of actinic keratosis (AK) were reported in 2 patients treated with sorafenib (Lacouture et al), but the scope of this observation has not been evaluated.
  • One patient receiving sorafenib at a 25% dose reduction developed a second invasive SCC lesion on his forearm 6 months after the initial resection.
  • [MeSH-major] Benzenesulfonates / adverse effects. Carcinoma, Squamous Cell / chemically induced. Drug Eruptions / etiology. Keratosis, Actinic / chemically induced. Protein Kinase Inhibitors / adverse effects. Pyridines / adverse effects. Skin Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Genitourin Cancer. 2009 Jan;7(1):9-10 [19213661.001]
  • (PMID = 19213663.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ NIHMS773866; NLM/ PMC4825856
  •  go-up   go-down


14. de Freitas Mda C, Ramalho LM, Xavier FC, Moreira AL, Reis SR: p53 and MDM2 protein expression in actinic cheilitis. J Appl Oral Sci; 2008 Nov-Dec;16(6):414-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and MDM2 protein expression in actinic cheilitis.
  • Actinic cheilitis is a potentially malignant lip lesion caused by excessive and prolonged exposure to ultraviolet radiation, which can lead to histomorphological alterations indicative of abnormal cell differentiation.
  • There are few published studies regarding the p53 and MDM2 proteins in actinic cheilitis.
  • Fifty-eight cases diagnosed with actinic cheilitis were histologically evaluated using Banóczy and Csiba (1976) parameters, and were subjected to immunohistochemical analysis using the streptavidin-biotin method in order to assess p53 and MDM2 protein expression.
  • The expression of p53 and MDM2 proteins in actinic cheilitis can be an important indicator in lip carcinogenesis, regardless of the degree of epithelial dysplasia.

  • Genetic Alliance. consumer health - Actinic Cheilitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082401.001).
  • [ISSN] 1678-7765
  • [Journal-full-title] Journal of applied oral science : revista FOB
  • [ISO-abbreviation] J Appl Oral Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Chromatin; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ PMC4327713
  •  go-up   go-down


15. Sidoroff A, Thaler P: Taking treatment decisions in non-melanoma skin cancer--the place for topical photodynamic therapy (PDT). Photodiagnosis Photodyn Ther; 2010 Mar;7(1):24-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Epithelial non-melanoma skin cancer (NMSC) like actinic keratosis (AK), Bowen's disease (BD) and basal cell carcinoma (BCC) represent the most common malignancies in the fair skinned population.
  • Epidemiological data reveal high incidences, especially for actinic keratoses, which are basically non-invasive squamous cell carcinomas, but fortunately bear a low risk of mortality for a single lesion.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier B.V. All rights reserved.
  • [CommentIn] Photodiagnosis Photodyn Ther. 2010 Mar;7(1):15 [20230988.001]
  • (PMID = 20230990.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 144O8QL0L1 / Diclofenac
  • [Number-of-references] 98
  •  go-up   go-down


16. Dianzani C, Pierangeli A, Chiricozzi A, Avola A, Degener AM: Cutaneous human papillomaviruses as recurrence factor in actinic keratoses. Int J Immunopathol Pharmacol; 2008 Jan-Mar;21(1):145-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous human papillomaviruses as recurrence factor in actinic keratoses.
  • Actinic keratoses (AK) are common, premalignant lesions cause mainly by UV DNA damage.
  • The aim of this work is to identify the presence of HPV DNA in biopsies from Actinic Keratoses (AK) and from normal skin samples collected from dermatological healthy subjects in Italy, in order to evaluate the severity and the clinical evolution of the HPV positive lesions.
  • These data permit to hypothesize that the presence of HPV DNA could be an aggravating factor for AK lesion severity and recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336740.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


17. Ulrich M, Forschner T, Röwert-Huber J, González S, Stockfleth E, Sterry W, Astner S: Differentiation between actinic keratoses and disseminated superficial actinic porokeratoses with reflectance confocal microscopy. Br J Dermatol; 2007 May;156 Suppl 3:47-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between actinic keratoses and disseminated superficial actinic porokeratoses with reflectance confocal microscopy.
  • BACKGROUND: Clinical differentiation between actinic keratosis (AK) and disseminated superficial actinic porokeratosis (DSAP) may pose a significant challenge, and histological evaluation is often also required for diagnosis.
  • OBJECTIVES: The aim of this study was to determine the relevant RCM criteria for the identification of disseminated superficial actinic porokeratoses (DSAPs) and to define distinguishing criteria for DSAPs compared with actinic keratosis (AKs).
  • All lesions were evaluated by clinical examination, and RCM and one clinically identified lesion was biopsied for histological confirmation.
  • RESULTS: Cellular and nuclear atypia, inflammation, spongiosis, parakeratosis and changes in epidermal architecture were present in both lesion types (i.e.
  • CONCLUSIONS: Distinguishing features of DSAPs, such as cornoid lamella, sharp demarcation of the lesion and focal keratinocyte atypia are easily identifiable using RCM, and correlate well with histopathology.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488407.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


18. Khondker L, Wahab MA, Khan SI: Profile of lichen planus in Bangladesh. Mymensingh Med J; 2010 Apr;19(2):250-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regarding site of onset of lesion, lesions were highest 100(83.33%) in upper limbs, next lower limbs, trunk, oral mucosa etc.
  • The distribution of clinical pattern of lichen planus showing classic pattern (68.33%) was the most common type, followed by hypertrophic, actinic, ashy dermatoses, lichen plano-pilaris, erosive or ulcerative etc.
  • This clinico-epidemiological study of lichen planus attending in the different hospital in Dhaka, Bangladesh has shown that lichen planus is usually associated with 30 to 50 years of age group, with higher male prevalence than female, 15 days to 6 months are mainly duration of disease, koebnerization and Wickhams striae are common clinical signs, upper limbs is mainly the site of onset of lesion, and classic pattern is the most common clinical type in lichen planus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395921.001).
  • [ISSN] 1022-4742
  • [Journal-full-title] Mymensingh medical journal : MMJ
  • [ISO-abbreviation] Mymensingh Med J
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Bangladesh
  •  go-up   go-down


19. Ortonne JP, Gupta G, Ortonne N, Duteil L, Queille C, Mallefet P: Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment. Exp Dermatol; 2010 Jul 1;19(7):641-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment.
  • BACKGROUND: During treatment of actinic keratosis (AK) lesions with imiquimod sub-clinical lesions often become visible.
  • Patients were assessed for baseline AK lesion counts (clinical and sub-clinical) at the screening visit and final counts at week 20.
  • The FD lesion counting method did not show a significant increase in the number of detected lesions compared with clinical analysis in the imiquimod and placebo groups but when comparisons were performed using pooled data (treatments and visits combined) the results were significant.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Keratosis, Actinic / diagnosis. Keratosis, Actinic / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201959.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Levulinic Acids; 0 / Photosensitizing Agents; 3Q95S830W6 / methyl levulinate; 99011-02-6 / imiquimod
  •  go-up   go-down


20. Campione E, Diluvio L, Paternò EJ, Chimenti S: Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score. Am J Clin Dermatol; 2010;11(1):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score.
  • OBJECTIVE: To evaluate the efficacy and tolerability of piroxicam 1% gel in the treatment of actinic keratoses.
  • METHODS: Piroxicam 1% gel was applied twice daily for 12 weeks to 31 actinic keratoses.
  • Changes were evaluated using a new scoring system (AKESA), based on the clinical presence of erythema, scale, and atrophy on a target lesion.
  • In our experience, the use of piroxicam 1% gel for 90 days induced complete regression in 48% of evaluated actinic keratoses, corresponding to keratotic and verrucous clinical variants.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Dermatologic Agents / therapeutic use. Keratosis, Actinic / drug therapy. Piroxicam / therapeutic use. Skin Neoplasms / prevention & control. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20000874.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Dermatologic Agents; 0 / Gels; 13T4O6VMAM / Piroxicam; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


21. Shah AY, Doherty SD, Rosen T: Actinic cheilitis: a treatment review. Int J Dermatol; 2010 Nov;49(11):1225-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic cheilitis: a treatment review.
  • All other factors being equal, the presence of actinic cheilitis, a pre-invasive malignant lesion of the lips, doubles the risk of squamous cell carcinoma developing in this anatomic area.
  • This paper critically evaluates the available medical literature to highlight the evidence-based strength of each recommended therapy for actinic cheilitis.

  • Genetic Alliance. consumer health - Actinic Cheilitis.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. TRICHLOROACETIC ACID .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The International Society of Dermatology.
  • (PMID = 20964646.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Caustics; 5V2JDO056X / Trichloroacetic Acid; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil; Actinic cheilitis
  •  go-up   go-down


22. Annemans L, Caekelbergh K, Roelandts R, Boonen H, Leys C, Nikkels AF, van Den Haute V, van Quickenborne L, Verhaeghe E, Leroy B: Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma. Eur J Dermatol; 2008 Sep-Oct;18(5):539-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma.
  • Clinical trials have shown that photodynamic therapy using methyl aminolevulinate (MAL-PDT) is an effective treatment for actinic keratosis (AK), and nodular and superficial basal cell carcinoma (nBCC and sBCC) unsuitable for other available therapies.
  • Total cost per lesion was euro 58 for AK (identical to model prediction), euro 316 for nBCC and euro 178 for sBCC (both within 20% of model prediction).
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / economics. Keratosis, Actinic / drug therapy. Keratosis, Actinic / economics. Photochemotherapy / economics. Photosensitizing Agents / economics. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy. Skin Neoplasms / economics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18693157.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


23. Harradine KA, Ridd K, Saunier EF, Clermont FF, Perez-Losada J, Moore DH, Epstein EH Jr, Bastian BC, Akhurst RJ: Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. Clin Cancer Res; 2009 Aug 15;15(16):5101-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, P-Smad1/5/8, a marker of activation of the bone morphogenetic protein signaling pathway, was generally not expressed at higher levels in patients taking ARDs, including analysis of nonlesional skin, actinic keratoses, carcinoma in situ, or squamous cell carcinoma but was differentially expressed between keratoacanthoma from transplant recipients compared with those from non-transplant recipients (P < or = 0.005).
  • Disparate P-Smad1/5/8 expression levels between keratoacanthoma from the two patient groups might reflect the distinct BMP-responsive cell of origin for this hair follicle-derived lesion.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2007 Dec;8(12):970-82 [18000526.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):313-27 [17936557.001]
  • [Cites] Nature. 2008 Jan 17;451(7176):340-4 [18202659.001]
  • [Cites] Cell. 2008 Jan 25;132(2):299-310 [18243104.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):117-29 [11586292.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Transplantation. 2002 May 27;73(10):1565-72 [12042641.001]
  • [Cites] Nat Cell Biol. 2002 Jul;4(7):487-94 [12105419.001]
  • [Cites] Cancer Lett. 2002 Jul 26;181(2):165-71 [12175531.001]
  • [Cites] J Invest Dermatol. 2002 Aug;119(2):499-506 [12190876.001]
  • [Cites] Mol Cell Biol. 2002 Dec;22(23):8184-98 [12417722.001]
  • [Cites] Nat Cell Biol. 2003 May;5(5):410-21 [12717440.001]
  • [Cites] Transplantation. 2003 Aug 15;76(3):597-602 [12923450.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):397-406 [12963901.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] J Cell Biol. 2003 Nov 10;163(3):609-23 [14610062.001]
  • [Cites] J Clin Invest. 2008 Aug;118(8):2722-32 [18618014.001]
  • [Cites] J Invest Dermatol. 2008 Oct;128(10):2467-73 [18463679.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):2993-7 [14701870.001]
  • [Cites] Transplant Proc. 2004 Apr;36(3):698-9 [15110635.001]
  • [Cites] Br J Dermatol. 2004 May;150(5):949-57 [15149508.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4405-10 [15231647.001]
  • [Cites] Am J Pathol. 2004 Sep;165(3):741-51 [15331399.001]
  • [Cites] J Cell Biol. 1989 Feb;108(2):653-60 [2465297.001]
  • [Cites] J Clin Invest. 1990 Dec;86(6):1976-84 [2254455.001]
  • [Cites] Br J Dermatol. 1993 Sep;129(3):242-9 [8286220.001]
  • [Cites] Transplantation. 1994 Jun 27;57(12):1727-31 [8016876.001]
  • [Cites] Transplant Proc. 1995 Apr;27(2):1767-8 [7725494.001]
  • [Cites] Cell. 1996 Aug 23;86(4):531-42 [8752208.001]
  • [Cites] Transplantation. 1997 Apr 15;63(7):1037-9 [9112364.001]
  • [Cites] Transplantation. 1998 Feb 15;65(3):313-8 [9484745.001]
  • [Cites] Transplant Proc. 1998 Jun;30(4):1124-6 [9636456.001]
  • [Cites] Nature. 1999 Feb 11;397(6719):530-4 [10028970.001]
  • [Cites] Kidney Int. 1999 Aug;56(2):714-9 [10432413.001]
  • [Cites] Can Med Assoc J. 1965 Aug 7;93:272-3 [14328045.001]
  • [Cites] Circulation. 2004 Dec 21;110(25):3822-9 [15583082.001]
  • [Cites] Mech Ageing Dev. 2005 May;126(5):560-7 [15811425.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1714-23 [15937546.001]
  • [Cites] J Invest Dermatol. 2005 Sep;125(3):450-5 [16117784.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1657-67 [15905207.001]
  • [Cites] Science. 2006 Apr 7;312(5770):117-21 [16601194.001]
  • [Cites] Transplantation. 2006 Jun 15;81(11):1558-67 [16770245.001]
  • [Cites] Ann Med. 2006;38(6):403-14 [17008304.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Nov;6(7):565-78 [17100564.001]
  • [Cites] Stem Cells. 2006 Dec;24(12):2826-39 [16960130.001]
  • [Cites] Transplant Proc. 2006 Dec;38(10):3533-5 [17175324.001]
  • [Cites] JAMA. 2006 Dec 20;296(23):2823-31 [17179459.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5090-6 [17545585.001]
  • [Cites] Lancet Oncol. 2007 Oct;8(10):921-32 [17913661.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):903-7 [18026089.001]
  • (PMID = 19671862.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / P01 AR050440-050001; United States / NIAMS NIH HHS / AR / P01 AR050440-010001; United States / NIAMS NIH HHS / AR / AR050440-010002; United States / NIAMS NIH HHS / AR / AR050440; United States / NIAMS NIH HHS / AR / AR050440-050001; United States / NIAMS NIH HHS / AR / AR050440-010001; United States / NIAMS NIH HHS / AR / P01 AR050440-010002; United States / NIAMS NIH HHS / AR / P01 AR050440
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Morphogenetic Proteins; 0 / Immunosuppressive Agents; 0 / Receptors, Transforming Growth Factor beta; 0 / Smad Proteins; 0 / Transforming Growth Factor beta1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  • [Other-IDs] NLM/ NIHMS168644; NLM/ PMC2812428
  •  go-up   go-down


24. Gulia A, Altamura D, De Trane S, Micantonio T, Fargnoli MC, Peris K: Pigmented reticular structures in basal cell carcinoma and collision tumours. Br J Dermatol; 2010 Feb 1;162(2):442-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine of 14 BCCs presented a typical pigment network, due to the association of a BCC lesion with a naevus, solar lentigo or actinic keratosis; two BCCs located on the face showed a pseudonetwork, and three of 14 lesions displayed a network-like structure characterized by light-brown irregularly meshed short linear structures, histopathologically related to a hyperpigmentation of the basal layer of the epidermis.
  • CONCLUSIONS: The presence of a pigment network in the context of a BCC is uncommon, and it usually reflects the association of BCC with a solar lentigo, naevus or a specific location of the lesion on photodamaged skin.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19754866.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Melanins
  •  go-up   go-down


25. Dang C, Gottschling M, Manning K, O'Currain E, Schneider S, Sterry W, Stockfleth E, Nindl I: Identification of dysregulated genes in cutaneous squamous cell carcinoma. Oncol Rep; 2006 Sep;16(3):513-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to identify dysregulated genes, we examined the relative mRNA expression present in cutaneous SCC and its precursor lesion actinic keratosis (AK) by comparison to normal skin.


26. Gerster JF, Lindstrom KJ, Miller RL, Tomai MA, Birmachu W, Bomersine SN, Gibson SJ, Imbertson LM, Jacobson JR, Knafla RT, Maye PV, Nikolaides N, Oneyemi FY, Parkhurst GJ, Pecore SE, Reiter MJ, Scribner LS, Testerman TL, Thompson NJ, Wagner TL, Weeks CE, Andre JD, Lagain D, Bastard Y, Lupu M: Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. J Med Chem; 2005 May 19;48(10):3481-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While these compounds showed no direct antiviral activity when tested in a number of cell culture systems, some demonstrated potent inhibition of virus lesion development in an intravaginal guinea pig herpes simplex virus-2 assay.
  • The in vitro results reported herein and the in vivo results reported previously led to the discovery of imiquimod, 26, which was developed as a topical agent and has been approved for the treatment of genital warts, actinic keratosis, and superficial basal cell carcinoma.

  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15887957.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antiviral Agents; 0 / Imidazoles; 0 / Interferon Inducers; 0 / Quinolines; 9008-11-1 / Interferons; 99011-02-6 / imiquimod
  •  go-up   go-down


27. Schornagel IJ, Guikers KL, Van Weelden H, Brijnzeel-Koomen CA, Sigurdsson V: The polymorphous light eruption-severity assessment score does not reliably predict the results of phototesting. J Eur Acad Dermatol Venereol; 2008 Jun;22(6):675-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The score of each question was plotted as independent variable in a multiple linear regression model against the score of the phototest (minimal number of irradiations necessary to elicit a positive skin lesion, with a maximum of 6 irradiations) as dependent variable using an enter approach.
  • Phototesting is useful to determine the responsible ultraviolet action spectrum and to exclude differential diagnoses like photosensitive eczema, lupus erythematosus or chronic actinic dermatitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18393963.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


28. Lentini M, Schepis C, Cuppari DA, Batolo D: Tenascin expression in actinic keratosis. J Cutan Pathol; 2006 Nov;33(11):716-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tenascin expression in actinic keratosis.
  • Actinic keratoses (AKs) are intraepidermal neoplastic lesions of the sun-exposed skin.
  • RESULTS: Tenascin positivity was observed in all cases at the dermal level close to the epithelial lesion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083689.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Actins; 0 / Tenascin
  •  go-up   go-down


29. Martínez A, Spencer ML, Brethauer U, Grez P, Marchesani FJ, Rojas IG: Reduction of syndecan-1 expression during lip carcinogenesis. J Oral Pathol Med; 2009 Aug;38(7):580-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Actinic cheilitis (AC) is an oral pre-cancerous lesion that sometimes develops into lip squamous cell carcinoma (SCC).
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cheilitis / metabolism. Keratosis, Actinic / metabolism. Lip Neoplasms / metabolism. Syndecan-1 / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473447.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Syndecan-1
  •  go-up   go-down


30. Mantese SA, Diogo PM, Rocha A, Berbert AL, Ferreira AK, Ferreira TC: Cutaneous horn: a retrospective histopathological study of 222 cases. An Bras Dermatol; 2010 Mar-Apr;85(2):157-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cutaneous horn is a keratotic, conical and circumscribed lesion that can hide both benign or malignant lesions.
  • Within the group of pre-malignant lesions, actinic keratosis was found in 83,84% of the cases; within the group of malignant lesions, squamous cell carcinoma was found in 93,75% of the cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20520930.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


31. Nikkels AF, Piérard GE: Cryoscopy: a novel enhancing method of in vivo skin imaging. Skin Res Technol; 2007 Nov;13(4):377-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cryoscopy patterns of normal skin, callosities and of histologically proven seborrheic keratoses, verrucous hamartomas, molluscum contagiosum, keratoacanthomas, viral warts, condylomas, actinic keratoses, dermatofibromas, skin tags, basal cell carcinomas, angiomas, and melanocytic naevi were assessed.
  • Increased contrast of the skin surface texture was observed in almost every studied lesion.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Nitrogen, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908188.001).
  • [ISSN] 0909-752X
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] N762921K75 / Nitrogen
  •  go-up   go-down


32. Puizina-Ivić N, Sapunar D, Marasović D, Mirić L: An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis. Coll Antropol; 2008 Oct;32 Suppl 2:61-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis.
  • In this study the authors have analyzed imunohistochemically the expression of Bcl-2 protein in the histopathological variants of the most common malignant tumors of the skin--basal cell carcinoma (BCC) and squamous cell tumor (SCC), as well as in the precancerous lesion actinic keratosis (AK) and in benign tumor seborrheic keratosis (SK).
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratosis, Actinic / metabolism. Keratosis, Seborrheic / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Skin Neoplasms / metabolism


33. Vasiljevic N, Hazard K, Dillner J, Forslund O: Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis. J Gen Virol; 2008 Oct;89(Pt 10):2467-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis.
  • This study determined the complete genomes of four betapapillomaviruses of species 2 from skin lesions designated HPV-107, -110 and -111 and FA75[KI88-03], an isolate of an unpublished HPV type, and analysed their prevalence and viral loads in biopsies from SCC, actinic keratosis (AK), basal cell carcinoma, seborrhoeic keratosis and the healthy skin of 263 immunocompetent patients by HPV type-specific real-time PCR assays.
  • Seventeen patients (6.5 %) harboured at least one of the four HPV types in their lesion, whereas seven patients (2.7 %) harboured one or more of the HPV types in healthy skin.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18796715.001).
  • [ISSN] 0022-1317
  • [Journal-full-title] The Journal of general virology
  • [ISO-abbreviation] J. Gen. Virol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EF422221/ EU410347/ EU410348/ EU410349
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


34. Clouser MC, Harris RB, Roe DJ, Saboda K, Ranger-Moore J, Duckett L, Alberts DS: Risk group, skin lesion history, and sun sensitivity reliability in squamous cell skin cancer progression. Cancer Epidemiol Biomarkers Prev; 2006 Nov;15(11):2292-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk group, skin lesion history, and sun sensitivity reliability in squamous cell skin cancer progression.
  • Multiple questionnaires and screening protocols were administered over a 3-month period to individuals from three risk groups: existing sun damage on forearms but no visible actinic keratoses (n = 91), visible actinic keratoses (n = 38), and history of resected squamous cell skin cancer in the last 12 months (n = 35).
  • For self-reported NMSC lesion history between two interviews, 24 days apart, kappa estimates ranged from 0.66 to 0.78 and were higher for women than men.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119060.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA27502
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


35. Warino L, Tusa M, Camacho F, Teuschler H, Fleischer AB Jr, Feldman SR: Frequency and cost of actinic keratosis treatment. Dermatol Surg; 2006 Aug;32(8):1045-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency and cost of actinic keratosis treatment.
  • BACKGROUND: Actinic keratosis (AK) is a common lesion with its highest incidence in the aged population.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918567.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


36. Ribatti D, Nico B, Perra MT, Maxia C, Piras F, Murtas D, Crivellato E, Sirigu P: Correlation between NGF/TrkA and microvascular density in human pterygium. Int J Exp Pathol; 2009 Dec;90(6):615-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pterygium is a surface ocular lesion that is associated with chronic UV exposure.
  • The primary effect is a solar actinic elastosis within the stroma.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2000 Jun;109(4):829-37 [10929037.001]
  • [Cites] J Cell Mol Med. 2008 Dec;12(6B):2799-811 [19210757.001]
  • [Cites] Arch Dermatol Res. 2001 Jun;293(6):291-5 [11480588.001]
  • [Cites] Cornea. 2001 Oct;20(7):738-42 [11588427.001]
  • [Cites] FASEB J. 2002 Aug;16(10):1307-9 [12154004.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3430-7 [12407153.001]
  • [Cites] Curr Eye Res. 2002 Jul;25(1):17-22 [12518239.001]
  • [Cites] J Vet Sci. 2001 Aug;2(2):125-30 [14614283.001]
  • [Cites] Auton Neurosci. 2003 Oct 31;108(1-2):57-62 [14614965.001]
  • [Cites] Prog Brain Res. 2004;146:387-401 [14699975.001]
  • [Cites] Cancer Res. 1987 Oct 1;47(19):5155-61 [2441862.001]
  • [Cites] Science. 1987 Sep 4;237(4819):1154-62 [3306916.001]
  • [Cites] J Neurosci Res. 1992 Aug;32(4):461-70 [1326636.001]
  • [Cites] Acta Histochem. 1996 Apr;98(2):195-201 [8739304.001]
  • [Cites] Br J Ophthalmol. 1998 Jan;82(1):77-81 [9536887.001]
  • [Cites] Curr Eye Res. 1998 Oct;17(10):986-93 [9788301.001]
  • [Cites] Clin Exp Allergy. 2004 Nov;34(11):1660-4 [15544587.001]
  • [Cites] Can J Ophthalmol. 2005 Apr;40(2):185-7 [16049533.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2430-7 [16723453.001]
  • [Cites] Curr Pharm Des. 2006;12(21):2609-22 [16842161.001]
  • [Cites] J Cell Mol Med. 2007 May-Jun;11(3):585-9 [17635650.001]
  • [Cites] Eye (Lond). 2007 Aug;21(8):1095-101 [16823458.001]
  • [Cites] Med Hypotheses. 2007;69(4):925-7 [17367957.001]
  • [Cites] Curr Eye Res. 2008 Jan;33(1):23-8 [18214740.001]
  • [Cites] Microvasc Res. 2008 Mar;75(2):135-41 [17764704.001]
  • [Cites] Hepatology. 2001 Jan;33(1):148-58 [11124831.001]
  • (PMID = 19758420.001).
  • [ISSN] 1365-2613
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9061-61-4 / Nerve Growth Factor; EC 2.7.10.1 / Receptor, trkA
  • [Other-IDs] NLM/ PMC2803252
  •  go-up   go-down


37. Krupashankar DS, IADVL Dermatosurgery Task Force: Standard guidelines of care: CO2 laser for removal of benign skin lesions and resurfacing. Indian J Dermatol Venereol Leprol; 2008 Jan;74 Suppl:S61-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INDICATIONS FOR CO 2 LASER: Therapeutic indications: Actinic and seborrheic keratosis, warts, moles, skin tags, epidermal and dermal nevi, vitiligo blister and punch grafting, rhinophyma, sebaceous hyperplasia, xanthelasma, syringomas, actinic cheilitis angiofibroma, scar treatment, keloid, skin cancer, neurofibroma and diffuse actinic keratoses.
  • Choice of the machine and the parameters depends on the site, type of lesion, result needed, and the physician's experience.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688106.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] India
  • [Investigator] Mysore V; Sanant S; Khunger N; Patwardhan N; Prasad D; Buddhadev R; Chatterjee M; Gupta S; Shetty MK; Krupashankar DS; Rao KH; Vedamurthy M; Oberai C; Lahiri K; Sachidanand S; Joshipura S
  •  go-up   go-down


38. Alosh M: Modeling longitudinal count data with dropouts. Pharm Stat; 2010 Jan-Mar;9(1):35-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper explores the utility of different approaches for modeling longitudinal count data with dropouts arising from a clinical study for the treatment of actinic keratosis lesions on the face and balding scalp.
  • Finally, we consider a transition model where, unlike the previous approaches that model the log-link function of the mean response, we model the subject's actual lesion counts.
  • [MeSH-minor] Clinical Trials as Topic / methods. Humans. Keratosis, Actinic / mortality. Keratosis, Actinic / therapy. Longitudinal Studies. Statistics as Topic / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published in 2009 by John Wiley & Sons, Ltd.
  • (PMID = 19191272.001).
  • [ISSN] 1539-1612
  • [Journal-full-title] Pharmaceutical statistics
  • [ISO-abbreviation] Pharm Stat
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


39. Wiegell SR, Skiveren J, Philipsen PA, Wulf HC: Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate. Br J Dermatol; 2008 Apr;158(4):727-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To compare pain during PDT using two different fluence rates, and also to evaluate the association between pain and protoporphyrin IX (PpIX) fluorescence, lesion type, lesion preparation and lesion localization.
  • METHODS: Twenty-six patients with actinic keratoses (AKs) in different localizations and 34 patients with facial acne vulgaris were treated with methyl aminolaevulinate-PDT.

  • MedlinePlus Health Information. consumer health - Acne.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284396.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX
  •  go-up   go-down


40. Shaffelburg M: Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream. J Drugs Dermatol; 2009 Jan;8(1):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream.
  • BACKGROUND: Field-directed therapies for actinic keratosis include photodynamic therapy and imiquimod.
  • METHODS: The entire face of adults with > or =10 facial actinic keratoses were treated with photodynamic therapy with aminolevulinic acid 20% at baseline and at month 1.
  • Lesion counts were performed at baseline and months 1, 2, 3, 4, 6, and 12; and local skin reactions assessments at months 2, 3, 4, and 6.
  • At month 12, median lesion reductions was 89.9% versus 74.5% (P=.0023), respectively.
  • CONCLUSIONS: Photodynamic therapy followed by imiquimod was well tolerated and improved reduction of actinic keratoses.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Keratosis, Actinic / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use

  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180894.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Photosensitizing Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


41. Kvlividze O, Gogiashvili L, Burkadze G: The characteristics of human papillomavirus expression and cell proliferation in actinic keratosis and Bowen's disease of the skin. Georgian Med News; 2006 Jul;(136):108-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The characteristics of human papillomavirus expression and cell proliferation in actinic keratosis and Bowen's disease of the skin.
  • The aim of our study was to elucidate the characteristics of HPV expression and cell proliferation in actinic keratosis and Bowen's disease of the skin.
  • We examined immunocompetent patients with premalignant lesions of the skin such as actinic keratosis and Bowen's disease.
  • Clinical study included gross features of lesion, growth rate, colour, size.
  • Actinic keratosis and Bowen's disease failed to show the specific clinical features, therefore, they can not be diagnosed based on clinical signs only and morphological examination seems to be mandatory.
  • The immunohistochemical study has showed that in both actinic keratosis and Bowen's disease HPV was positive in 60%, and 40% were HPV-negative suggesting the similar incidence of HPV infection in these premalignant lesions.
  • Our results suggest that HPV(+)/p53(+) types of actinic keratosis and Bowen's disease are characterized by higher proliferation activity in comparison to HPV(-)/p53(+) types, and expression of Bcl-2 is associated with HPV-negativity, therefore, these premalignant lesions of the skin require immunohistochemical examination with evaluation of expressions of human papillomavirus, proliferation marker PCNA and anti-apoptotic protein Bcl-2.
  • The differential diagnosis of actinic keratosis and Bowen's disease should be based on the following immunohistochemical criteria: incidences of positivity for p53, Bcl-2 and PCNA are similar, but expression intensity and anatomical localization are different: their expressions are higher in Bowen's disease, positive cells are found primarily in upper epidermis in actinic keratosis, while whole epithelium is involved in Bowen's disease.


42. Figueiredo EG, Paiva WS, Teixeira MJ: Extremely late development of pituitary carcinoma after surgery and radiotherapy. J Neurooncol; 2009 Apr;92(2):219-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After three years he presented worsening of visual deficits and MRI evidenced recurrence of the lesion.
  • Further treatment was not recommended by radiotherapists due previous actinic treatments.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 2001 Oct;55(4):549-56 [11678840.001]
  • [Cites] Henry Ford Hosp Med J. 1984;32(1):61-6 [6746304.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):765-70; discussion 770-1 [8692397.001]
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] J Neurosurg. 2002 Feb;96(2):352-60 [11838811.001]
  • [Cites] Neurosurg Focus. 2004 Apr 15;16(4):E7 [15191336.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1233-9; discussion 1239-40 [10807257.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):804-12 [9024719.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Feb;76(2):529-33 [8432799.001]
  • [Cites] Br J Radiol. 2000 Jul;73(871):783-5 [11089473.001]
  • [Cites] J Endocrinol Invest. 2002 Jan;25(1):65-72 [11883868.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):255-8 [14558601.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):402-8 [12924717.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Apr;78(4):842-6 [8157709.001]
  • [Cites] J Endocrinol Invest. 1997 Apr;20(4):230-6 [9211132.001]
  • (PMID = 19034384.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Kodama M, Watanabe D, Akita Y, Tamada Y, Matsumoto Y: Photodynamic therapy for the treatment of actinic cheilitis. Photodermatol Photoimmunol Photomed; 2007 Oct;23(5):209-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for the treatment of actinic cheilitis.
  • Although actinic cheilitis is a common disease, it should be treated carefully because it can undergo malignant transformation.
  • We report a case of actinic cheilitis treated with photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA), with satisfactory outcome in both clinical and pathological aspects.
  • Actinic cheilitis is a pathologic condition affecting mainly the lower lip caused by long-term exposure of the lips to the UV radiation in sunlight.
  • Analogous to actinic keratosis of the skin, actinic cheilitis is considered as a precancerous lesion and it may develop into squamous cell carcinoma.
  • We report a case of actinic cheilitis treated with PDT using ALA, with satisfactory outcome in both clinical and pathological aspects.

  • Genetic Alliance. consumer health - Actinic Cheilitis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17803601.001).
  • [ISSN] 0905-4383
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


44. Gomes AP, Johann JE, Lovato GG, Ferreira AM: Comparative analysis of the mast cell density in normal oral mucosa, actinic cheilitis and lip squamous cell carcinoma. Braz Dent J; 2008;19(3):186-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of the mast cell density in normal oral mucosa, actinic cheilitis and lip squamous cell carcinoma.
  • Actinic cheilitis (AC) is a lesion caused by excessive exposure to sunlight that can transform into lip squamous cell carcinoma.
  • The aim of this study was to compare the number of mast cells in 4 groups: NOM = normal oral mucosa (n=6); MDAC = mild dysplasia in actinic cheilitis (n=13); SDAC = severe dysplasia in actinic cheilitis (n=13); and LSCC = lip squamous cell carcinoma (n=15).


45. Richtig E, Ahlgrimm-Siess V, Koller S, Gerger A, Horn M, Smolle J, Hofmann-Wellenhof R: Follow-up of actinic keratoses after shave biopsy by in-vivo reflectance confocal microscopy--a pilot study. J Eur Acad Dermatol Venereol; 2010 Mar;24(3):293-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up of actinic keratoses after shave biopsy by in-vivo reflectance confocal microscopy--a pilot study.
  • BACKGROUND: Monitoring of treatment efficacy after shave biopsy of actinic keratoses (AK) is often difficult, as clinical and dermoscopic features may not be reliable.
  • After 12 months, one lesion of these two lesions changed into NS in RCM, whereas the other lesion progressed into clinical visible AK.
  • [MeSH-major] Biopsy / methods. Keratosis, Actinic / pathology. Microscopy, Confocal / methods

  • MedlinePlus Health Information. consumer health - Biopsy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19732253.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


46. Menter A, Vamvakias G, Jorizzo J: One-week treatment with once-daily fluorouracil cream 0.5% in participants with actinic keratoses. Cutis; 2008 Jun;81(6):509-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One-week treatment with once-daily fluorouracil cream 0.5% in participants with actinic keratoses.
  • Actinic keratoses (AKs) are common in fair-skinned individuals with a history of chronic and excessive sun exposure and may progress to squamous cell carcinoma (SCC).
  • Extending treatment for up to 4 weeks will further improve AK lesion clearance rates.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18666394.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Immunosuppressive Agents; U3P01618RT / Fluorouracil
  • [Number-of-references] 27
  •  go-up   go-down


47. Ricci E, Afaragan M: The effect of stochastic electrical noise on hard-to-heal wounds. J Wound Care; 2010 Mar;19(3):96-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ulcer aetiologies were: EPUAP grade IV pressure ulcers (n=6) and grade III pressure ulcer (n=1), vasculitic ulcer (n=1), post-actinic lesion (n=1), ischaemic (n=1) and post-surgical lesion (n=1).

  • MedlinePlus Health Information. consumer health - Wounds and Injuries.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20559186.001).
  • [ISSN] 0969-0700
  • [Journal-full-title] Journal of wound care
  • [ISO-abbreviation] J Wound Care
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


48. Zhao B, He YY: Recent advances in the prevention and treatment of skin cancer using photodynamic therapy. Expert Rev Anticancer Ther; 2010 Nov;10(11):1797-809
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After treatment with ALA or methyl 5-aminolevulinate, protoporphyrin IX preferentially accumulates in the lesion area of various skin diseases, which allows not only PDT treatment but also fluorescence diagnosis with ALA-induced porphyrins.
  • Susceptible lesions include various forms of non-melanoma skin cancer such as actinic keratosis, basal cell carcinoma and squamous cell carcinoma.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):254-8 [16948827.001]
  • [Cites] Acta Derm Venereol. 2006;86(5):418-21 [16955186.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1029-36 [17034536.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2006 Nov-Dec;22(6):498-9 [17117119.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):5-14 [17126737.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):89-94 [17126746.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):95-100 [17126747.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):320-8 [17223873.001]
  • [Cites] Arch Dermatol. 2007 Feb;143(2):264-5 [17310011.001]
  • [Cites] Expert Opin Drug Deliv. 2007 Mar;4(2):131-48 [17335411.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Apr;21(4):439-51 [17373968.001]
  • [Cites] Br J Dermatol. 2007 May;156(5):793-801 [17419691.001]
  • [Cites] Br J Dermatol. 2007 Jul;157(1):87-91 [17501954.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Aug;4(8):462-9 [17657251.001]
  • [Cites] Arch Dermatol. 2007 Sep;143(9):1131-6 [17875873.001]
  • [Cites] Photomed Laser Surg. 2007 Oct;25(5):428-35 [17975957.001]
  • [Cites] Clin Transl Oncol. 2008 Mar;10(3):148-54 [18321817.001]
  • [Cites] Br J Dermatol. 2008 May;158(5):994-9 [18341663.001]
  • [Cites] Br J Pharmacol. 2008 May;154(1):1-3 [18362894.001]
  • [Cites] J Am Chem Soc. 2008 Aug 13;130(32):10643-7 [18642918.001]
  • [Cites] Eur J Dermatol. 2008 Sep-Oct;18(5):547-53 [18693158.001]
  • [Cites] Trends Biotechnol. 2008 Nov;26(11):612-21 [18804298.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Dec 14;60(15):1627-37 [18930086.001]
  • [Cites] Br J Dermatol. 2008 Dec;159(6):1245-66 [18945319.001]
  • [Cites] Exp Dermatol. 2009 Feb;18(2):116-21 [18643849.001]
  • [Cites] Chem Commun (Camb). 2009 Mar 28;(12):1475-7 [19277361.001]
  • [Cites] Photodiagnosis Photodyn Ther. 2008 Jun;5(2):127-33 [19356643.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2009 May;23(5):505-16 [19175703.001]
  • [Cites] Br J Dermatol. 2009 Jun;160(6):1308-14 [19416257.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2009 Jul;29(7):992-1000 [19057023.001]
  • [Cites] Nat Med. 2009 Jul;15(7):713 [19584845.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Dec 1;241(2):163-72 [19695274.001]
  • [Cites] J Pathol. 2009 Dec;219(4):400-9 [19771562.001]
  • [Cites] Immunol Res. 2010 Mar;46(1-3):216-26 [19763892.001]
  • [Cites] Arch Dermatol. 2010 Mar;146(3):283-7 [20231499.001]
  • [Cites] Eur J Dermatol. 2000 Oct-Nov;10(7):568-75; discussion 576 [11056436.001]
  • [Cites] Ophthalmology. 2000 Dec;107(12):2314-7 [11186878.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2000 Jul;14(4):298-300 [11204521.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Mar;15(3):311-21 [11207506.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] Br J Dermatol. 2001 Jun;144(6):1207-14 [11422043.001]
  • [Cites] Br J Dermatol. 2001 Sep;145(3):467-71 [11531838.001]
  • [Cites] J Photochem Photobiol B. 2001 Sep 15;62(3):140-5 [11566277.001]
  • [Cites] Photochem Photobiol. 2001 Nov;74(5):656-69 [11723793.001]
  • [Cites] J Chemother. 2001 Oct;13(5):494-502 [11760213.001]
  • [Cites] J Photochem Photobiol B. 2002 Mar;66(2):89-106 [11897509.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2005 Jun;21(3):142-9 [15888131.001]
  • [Cites] J Photochem Photobiol B. 2005 Jun 1;79(3):231-41 [15896650.001]
  • [Cites] Australas J Dermatol. 2005 Aug;46(3):196-8 [16008656.001]
  • [Cites] Br J Dermatol. 2005 Sep;153(3):672-4 [16120168.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Dec;56(6):569-77 [16001166.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):791-800 [16221049.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5 Suppl 1):S273-6 [16227107.001]
  • [Cites] Br J Dermatol. 2006 Jan;154(1):146-9 [16403108.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):569-74 [16374480.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):542-4 [16482195.001]
  • [Cites] J Am Acad Dermatol. 2006 Mar;54(3):524-6 [16488310.001]
  • [Cites] Br J Dermatol. 2002 Apr;146(4):552-67 [11966684.001]
  • [Cites] Optom Vis Sci. 2002 Apr;79(4):218-24 [11999147.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3956-61 [12124326.001]
  • [Cites] Lasers Med Sci. 2002;17(3):173-86 [12181632.001]
  • [Cites] Clin Exp Dermatol. 2002 Sep;27(6):516-8 [12372098.001]
  • [Cites] Methods Mol Med. 2003;75:507-26 [12407761.001]
  • [Cites] J Photochem Photobiol B. 2003 Feb;69(2):121-7 [12633984.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] J Am Chem Soc. 2003 Jul 2;125(26):7860-5 [12823004.001]
  • [Cites] Mol Immunol. 2003 Jul;39(17-18):1133-6 [12835091.001]
  • [Cites] J Dermatolog Treat. 2003;14 Suppl 3:23-6 [14522638.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3591-600 [14666654.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1242-9 [14674903.001]
  • [Cites] Dermatol Surg. 2004 Jan;30(1):63-6 [14692930.001]
  • [Cites] Transplantation. 2004 Jan 15;77(1):115-21 [14724445.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):116-20 [14732670.001]
  • [Cites] J Am Acad Dermatol. 2004 Mar;50(3):363-7 [14988676.001]
  • [Cites] Br J Dermatol. 2004 Feb;150(2):337-40 [14996106.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):295-300 [15069697.001]
  • [Cites] Br J Dermatol. 2004 Jun;150(6):1061-9 [15214890.001]
  • [Cites] Australas J Dermatol. 2004 Aug;45(3):172-4 [15250896.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):196-200 [15270891.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Aug;5(4):397-408 [15320770.001]
  • [Cites] Br J Dermatol. 2004 Aug;151(2):472-80 [15327557.001]
  • [Cites] Onkologie. 2004 Aug;27(4):407-11 [15347900.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 May;130(5):279-84 [14997383.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] J Photochem Photobiol B. 1990 Jun;6(1-2):143-8 [2121931.001]
  • [Cites] Aust N Z J Surg. 1991 May;61(5):340-8 [2025186.001]
  • [Cites] Photochem Photobiol. 1991 Nov;54(5):659 [1798741.001]
  • [Cites] Photochem Photobiol. 1992 Jun;55(6):931-48 [1409894.001]
  • [Cites] Arch Dermatol Res. 1995;287(7):665-74 [8534131.001]
  • [Cites] J Urol. 1996 Jan;155(1):105-9; discussion 109-10 [7490803.001]
  • [Cites] Photochem Photobiol. 1996 Jun;63(6):892-7 [8992510.001]
  • [Cites] Dermatology. 1996;192(3):246-51 [8726640.001]
  • [Cites] J Photochem Photobiol B. 1996 Nov;36(2):169-74 [9002254.001]
  • [Cites] J Photochem Photobiol B. 1996 Nov;36(2):199-204 [9002261.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2282-308 [9191516.001]
  • [Cites] Arch Dermatol. 1997 Jun;133(6):727-32 [9197826.001]
  • [Cites] Photochem Photobiol. 1997 Oct;66(4):493-6 [9337620.001]
  • [Cites] Aesthetic Plast Surg. 1997 Nov-Dec;21(6):437-9 [9354609.001]
  • [Cites] Arch Dermatol. 1998 Feb;134(2):207-14 [9487213.001]
  • [Cites] J Invest Dermatol. 1998 May;110(5):746-51 [9579539.001]
  • [Cites] Australas J Dermatol. 1998 May;39(2):63-8; quiz 69-70 [9611372.001]
  • [Cites] J Clin Laser Med Surg. 1996 Oct;14(5):219-21 [9612186.001]
  • [Cites] Acta Derm Venereol. 1999 Jan;79(1):54-61 [10086861.001]
  • [Cites] Br J Dermatol. 1999 Mar;140(3):514-7 [10233277.001]
  • [Cites] J Invest Dermatol. 1959 Feb;32(2, Part 2):229-31 [13641790.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Jan 7;44(3):419-23 [15624158.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):13-8 [15672050.001]
  • [Cites] Breast. 2005 Feb;14(1):65-7 [15695084.001]
  • [Cites] Br J Dermatol. 2005 Apr;152(4):765-72 [15840111.001]
  • [Cites] Br J Dermatol. 2000 Feb;142(2):338-9 [10730770.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):825-6 [10792247.001]
  • [Cites] Cancer. 2000 May 15;88(10):2275-82 [10820349.001]
  • [Cites] J Invest Dermatol. 2000 Sep;115(3):396-401 [10951274.001]
  • [Cites] J Urol. 2006 Apr;175(4):1201-7 [16515960.001]
  • [Cites] Br J Dermatol. 2006 Apr;154(4):747-50 [16536822.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2006;25(1-2):441-51 [16566734.001]
  • [Cites] Acta Derm Venereol. 2006;86(1):25-8 [16585985.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):551-6 [16700893.001]
  • [Cites] Int J Dermatol. 2006 May;45(5):489-98 [16700779.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):729-35 [16785375.001]
  • (PMID = 21080805.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES016936-01A2; United States / NCI NIH HHS / CA / P30 CA014599; United States / NIEHS NIH HHS / ES / R01 ES016936; United States / Intramural NIH HHS / / ZIA ES050117-21; United States / NIEHS NIH HHS / ES / ES016936-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS263919; NLM/ PMC3030451
  •  go-up   go-down


49. Nelson C, Rigel D: Long-term Follow up of Diclofenac Sodium 3% in 2.5% Hyaluronic Acid Gel for Actinic Keratosis: One-year Evaluation. J Clin Aesthet Dermatol; 2009 Jul;2(7):20-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term Follow up of Diclofenac Sodium 3% in 2.5% Hyaluronic Acid Gel for Actinic Keratosis: One-year Evaluation.
  • OBJECTIVE: To evaluate the long-term effects of treatment with diclofenac sodium 3% in 2.5% hyaluronic acid gel on clinically diagnosed actinic keratosis lesions in well-defined skin areas.
  • PARTICIPANTS: Patients who had completed the initial treatment phase with no further treatment for actinic keratosis in the designated treatment blocks.
  • MEASUREMENTS: The primary endpoint was the proportion of patients achieving 75-percent clearance of actinic keratosis lesions at one-year follow up based on percent change from baseline in target lesion number score or cumulative lesion number score.
  • Secondary endpoints were the proportion of patients achieving 100-percent actinic keratosis lesion clearance and change in investigator's global improvement index scores.
  • RESULTS: Eighty-one percent of patients reported no additional treatment for actinic keratosis lesions for one year after completing treatment with diclofenac sodium 3% gel.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Dermatol. 2007;8(4):195-200 [17645375.001]
  • [Cites] Br J Dermatol. 2007 May;156 Suppl 3:53-6 [17488408.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:21-4 [18067627.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:34-40 [18067630.001]
  • [Cites] Eur J Dermatol. 2008 Jan-Feb;18(1):6-10 [18086582.001]
  • [Cites] Eur J Dermatol. 2008 Nov-Dec;18(6):651-9 [18955209.001]
  • [Cites] Arch Dermatol. 1991 Jul;127(7):1029-31 [2064402.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] J Am Acad Dermatol. 1997 Apr;36(4):650-3 [9092763.001]
  • [Cites] Dermatol Surg. 1997 Nov;23(11):1009-19; quiz 1020-1 [9391557.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1306-11 [10728691.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):728-32 [10940057.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2000 Nov;63(1-2):15-23 [11104338.001]
  • [Cites] Int J Dermatol. 2001 Nov;40(11):709-13 [11737438.001]
  • [Cites] Arch Dermatol. 2003 Jan;139(1):66-70 [12533168.001]
  • [Cites] Skin Pharmacol Physiol. 2004 Mar-Apr;17(2):67-76 [14976383.001]
  • [Cites] J Drugs Dermatol. 2004 Jul-Aug;3(4):401-7 [15303784.001]
  • [Cites] Dermatol Surg. 2005 Jun;31(6):659-64 [15996416.001]
  • [Cites] J Drugs Dermatol. 2006 Feb;5(2):156-9 [16485883.001]
  • [Cites] Int J Dermatol. 2007 Jan;46(1):12-8 [17214714.001]
  • [Cites] Br J Dermatol. 2007 May;156 Suppl 3:18-24 [17488402.001]
  • [Cites] Br J Dermatol. 2007 May;156 Suppl 3:25-33 [17488403.001]
  • [Cites] J Drugs Dermatol. 2007 Jul;6(7):712-7 [17763595.001]
  • (PMID = 20729966.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2924138
  •  go-up   go-down


50. Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S: Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol; 2010 Apr;62(4):573-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
  • BACKGROUND: Imiquimod 5% cream is approved as a 16-week regimen for the treatment of actinic keratoses involving a 25-cm(2) area of skin.
  • Median baseline lesion counts for the treatment groups were 9 to 10.
  • Median reductions from baseline in lesion count were 23.6%, 66.7%, and 80.0% for the placebo, imiquimod 2.5%, and imiquimod 3.75% groups, respectively (P < .001 each imiquimod vs placebo).
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Keratosis, Actinic / drug therapy

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20133012.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Dosage Forms; 99011-02-6 / imiquimod
  •  go-up   go-down


51. Mizutani K, Watanabe D, Akita Y, Akimoto M, Tamada Y, Matsumoto Y: Photodynamic therapy using direct-current pulsed iontophoresis for 5-aminolevulinic acid application. Photodermatol Photoimmunol Photomed; 2009 Oct;25(5):280-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we attempted to reduce the absorption period in PDT by ionizing ALA using direct-current pulsed iontophoresis to treat actinic keratosis (AK).
  • Skin biopsies from the treated lesion showed the disappearance of tumour cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19747250.001).
  • [ISSN] 1600-0781
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


52. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H, European Skin Academy: Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol; 2008 Nov-Dec;18(6):651-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a treatment algorithm for actinic keratoses: a European Consensus.
  • Actinic keratoses (AKs) are lesions caused by chronic UV radiations that have the potential to progress to invasive SCCs.
  • The result of these discussions is an algorithm designed to assist physicians with their treatment decisions, giving recommendations for both field directed and lesion directed treatment.
  • [MeSH-major] Keratosis, Actinic / therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955209.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


53. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA: Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol; 2006;86(1):25-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An open intra-patient randomized study investigated the prevention potential of this treatment in 27 renal transplant patients with actinic keratoses and other skin lesions in two circular contralateral areas (5 cm diameter).
  • The mean time to occurrence of the first new lesion was significantly longer in treated than control areas (9.6 vs 6.8 months, treatment difference 2.9 [95% confidence interval 0.2 to 5.5] months, p = 0.034).

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16585985.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


54. Oyama N, Kaneko F: Trichilemmal carcinoma arising in seborrheic keratosis: a case report and published work review. J Dermatol; 2008 Dec;35(12):782-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The secondary skin malignancies arising in seborrheic keratosis (SK) are uncommon, and the causal association between the pre-existing lesion and subsequent malignant transformation remains uncertain.
  • Four of five cases (80%) developed the tumors in non-sun-exposed SK, and indeed had no apparent actinic damage in the histology.


55. Fernández-Guarino M, Harto A, Sánchez-Ronco M, Pérez-García B, Marquet A, Jaén P: [Retrospective, descriptive, observational study of treatment of multiple actinic keratoses with topical methyl aminolevulinate and red light: results in clinical practice and correlation with fluorescence imaging]. Actas Dermosifiliogr; 2008 Dec;99(10):779-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retrospective, descriptive, observational study of treatment of multiple actinic keratoses with topical methyl aminolevulinate and red light: results in clinical practice and correlation with fluorescence imaging].
  • BACKGROUND: Actinic keratosis (AK) is one of the most common skin diseases seen in clinical practice.
  • MATERIAL AND METHODS: In this retrospective, descriptive, observational study of 57 patients treated in our hospital with photodynamic therapy for multiple AKs, we recorded age, sex, and lesion site (face, scalp, and dorsum of the hands).
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Keratosis, Actinic / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19091216.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


56. Leonard N, Wilson N, Calonje JE: Squamomelanocytic tumor: an unusual and distinctive entity of uncertain biological potential. Am J Dermatopathol; 2009 Jul;31(5):495-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinically, the lesion was felt to be a melanocytic or vascular tumor but histologically was characterized by epithelioid cells with focal squamous differentiation.
  • The lesion has some similarities to a melanocytic matricoma but no evidence of matrical differentiation.
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Humans. Immunohistochemistry. Keratosis, Actinic / drug therapy. Male. Melanocytes / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542930.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


57. Orenstein A, Goldan O, Weissman O, Winkler E, Haik J: A new modality in the treatment of actinic cheilitis using the Er:YAG laser. J Cosmet Laser Ther; 2007 Mar;9(1):23-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new modality in the treatment of actinic cheilitis using the Er:YAG laser.
  • BACKGROUND: Cheilitis is a precancerous skin lesion most often affecting the lower lip.
  • OBJECTIVE: To evaluate the efficacy and outcome of a new modality in the treatment of actinic cheilitis with the Er:YAG laser.
  • METHODS: Between 2002 and 2005, 12 patients with actinic cheilitis were treated at our institute with the Er:YAG laser.

  • Genetic Alliance. consumer health - Actinic Cheilitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506137.001).
  • [ISSN] 1476-4172
  • [Journal-full-title] Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
  • [ISO-abbreviation] J Cosmet Laser Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


58. Neidecker MV, Davis-Ajami ML, Balkrishnan R, Feldman SR: Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics; 2009;27(6):451-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacoeconomic considerations in treating actinic keratosis.
  • Actinic keratosis is among the most commonly treated skin conditions in the outpatient setting.
  • With high prevalence, increasing incidence and the risk of transformation to a cancerous lesion, prevention and timely treatment present opportunities to rein in costs.
  • The purpose of this article is to review published economic studies relating to the treatment of actinic keratosis, to summarize results discussing the cost drivers of current treatment modalities and to identify parameters most likely to influence the cost effectiveness of treatment.
  • We systematically conducted a published literature search for pharmacoeconomic research of actinic keratosis using title, abstract or full-text searches with the following search terms ([actinic OR solar] AND [keratosis OR keratoses]) AND (economic OR cost OR pharmacoeconomics OR decision).
  • We included published articles referencing actinic keratosis in a standalone study or in a broader study referencing non-melanoma skin cancer and articles evaluating cost-of-illness, cost-of-treatment, cost minimization, cost effectiveness, cost utility, cost-benefit analysis and cost consequence.
  • Our review of the literature found nine studies devoted to pharmacoeconomic considerations of actinic keratosis treatments, with one article investigating both cost-of-illness and cost-of-treatment, two measuring cost-of-illness, two evaluating cost-of-treatment, one focusing on cost minimization, and three focusing on cost effectiveness.
  • The literature compared a broad range of actinic keratosis treatments including topical medications, cryotherapy, photodynamic therapy, excision and a combination of treatment modalities.
  • The direct cost of actinic keratosis management in the US was estimated at $US1.2 billion per year, with indirect costs totalling $US295 million (year 2004 values).
  • Pharmacoeconomic research defining standards, outcomes and areas of efficiencies in the treatment of actinic keratosis is in its infancy.
  • [MeSH-major] Cost of Illness. Economics, Pharmaceutical / statistics & numerical data. Keratosis, Actinic / economics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Surg. 2005 Jan;31(1):43-7 [15720095.001]
  • [Cites] Eur J Dermatol. 2006 Nov-Dec;16(6):599-606 [17229598.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S149-54 [18410801.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):8-10 [10607350.001]
  • [Cites] Pharmacoeconomics. 2004;22(2):83-94 [14731050.001]
  • [Cites] Eur J Dermatol. 2008 Sep-Oct;18(5):539-46 [18693157.001]
  • [Cites] Br J Dermatol. 2007 May;156 Suppl 3:40-2 [17488405.001]
  • [Cites] J Surg Oncol. 2001 Jun;77(2):76-8 [11398156.001]
  • [Cites] J Drugs Dermatol. 2008 Jan;7(1):23-5 [18246694.001]
  • [Cites] Arch Dermatol. 1991 Jul;127(7):1029-31 [2064402.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5):769-80 [18328594.001]
  • [Cites] Cutis. 2002 Aug;70(2 Suppl):30-6 [12353678.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):25-8 [10607354.001]
  • [Cites] Dermatol Surg. 2006 Aug;32(8):1045-9 [16918567.001]
  • [Cites] Med J Aust. 1983 Dec 10-24;2(12):619-22 [6669125.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Am J Epidemiol. 2007 Mar 15;165(6):719-26 [17204514.001]
  • [Cites] Epithelial Cell Biol. 1992 Jan;1(1):47-51 [1307938.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):222-30 [17223860.001]
  • [Cites] J Dermatolog Treat. 2009;20(5):266-75 [19421918.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] Br J Dermatol. 2006 Oct;155(4):784-90 [16965429.001]
  • [Cites] Health Aff (Millwood). 2004 Jan-Jun;Suppl Web Exclusives:W4-297-9 [15451996.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2196-8 [15152066.001]
  • [Cites] J Am Acad Dermatol. 1988 Dec;19(6):1045-52 [3204179.001]
  • [Cites] Dermatol Clin. 2006 Apr;24(2):271-80, viii [16677973.001]
  • [Cites] Br J Dermatol. 1994 Oct;131(4):455-64 [7947197.001]
  • [Cites] Int J Dermatol. 2006 Mar;45(3):272-6 [16533227.001]
  • [Cites] Pharmacoeconomics. 2004;22(18):1195-208 [15606226.001]
  • [Cites] Br J Dermatol. 2007 Jun;156(6):1393-4 [17535242.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] J Am Acad Dermatol. 2003 Mar;48(3):425-9 [12637924.001]
  • [Cites] Dermatol Ther. 2007 Sep-Oct;20(5):360-76 [18045361.001]
  • [Cites] J Invest Dermatol. 2000 Aug;115(2):273-7 [10951246.001]
  • [Cites] BMJ. 1996 Aug 3;313(7052):275-83 [8704542.001]
  • [Cites] Int J Dermatol. 2004 Sep;43(9):638-42 [15357741.001]
  • [Cites] J Am Acad Dermatol. 1999 Jul;41(1):81-99 [10411417.001]
  • [Cites] Ann Intern Med. 2008 Jun 17;148(12):956-61 [18483128.001]
  • [Cites] Am Fam Physician. 2007 Sep 1;76(5):667-71 [17894135.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:40-2 [14616348.001]
  • (PMID = 19640009.001).
  • [ISSN] 1170-7690
  • [Journal-full-title] PharmacoEconomics
  • [ISO-abbreviation] Pharmacoeconomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 48
  •  go-up   go-down


59. Akay BN, Kocyigit P, Heper AO, Erdem C: Dermatoscopy of flat pigmented facial lesions: diagnostic challenge between pigmented actinic keratosis and lentigo maligna. Br J Dermatol; 2010 Dec;163(6):1212-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatoscopy of flat pigmented facial lesions: diagnostic challenge between pigmented actinic keratosis and lentigo maligna.
  • BACKGROUND: The similarity between clinical pictures of pigmented actinic keratosis (PAK) and lentigo maligna (LM) is well known.
  • As dermatoscopic diagnosis of a pigmented skin lesion cannot be based on the presence of a single criterion, we may conclude that histopathology still remains the gold standard for correct diagnosis.
  • [MeSH-major] Facial Dermatoses / pathology. Hutchinson's Melanotic Freckle / pathology. Keratosis, Actinic / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. BJD © 2010 British Association of Dermatologists.
  • (PMID = 21083845.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Atasoy M, Anadolu-Braise R, Pirim I, Dogan H, Ikbal M: HLA Antigen Profile Differences in Patients with SCC (Squamous Cell Carcinoma) In-Situ /Actinic Keratosis and Invasive SCC: Is There a Genetic Succeptibility for Invasive SCC Development? Eurasian J Med; 2009 Dec;41(3):162-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA Antigen Profile Differences in Patients with SCC (Squamous Cell Carcinoma) In-Situ /Actinic Keratosis and Invasive SCC: Is There a Genetic Succeptibility for Invasive SCC Development?
  • OBJECTIVE: Actinic keratoses (AK) are proliferation of neoplastic keratinocytes confined to the epidermis induced by damaging solar ultraviolet radiation (UVR).
  • When the neoplastic keratinocytes extend in to papillary-reticular dermis, then the lesion termed as squamous cell carcinoma (SCC).
  • From dermatopathological point of view AK is clearly SCC in-situ, however although AK is a common lesion in Caucasians, not all AKs develop in to invasive SCC, at least not with the same biological pace.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25610095.001).
  • [ISSN] 1308-8734
  • [Journal-full-title] The Eurasian journal of medicine
  • [ISO-abbreviation] Eurasian J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC4261280
  • [Keywords] NOTNLM ; Actinic keratoses / HLA / Squamous cell carcinoma
  •  go-up   go-down


61. Braathen LR, Paredes BE, Saksela O, Fritsch C, Gardlo K, Morken T, Frølich KW, Warloe T, Solér AM, Ros AM: Short incubation with methyl aminolevulinate for photodynamic therapy of actinic keratoses. J Eur Acad Dermatol Venereol; 2009 May;23(5):550-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short incubation with methyl aminolevulinate for photodynamic therapy of actinic keratoses.
  • BACKGROUND: Photodynamic therapy (PDT) using methyl aminolevulinate (MAL) is an effective first-line treatment for actinic keratoses.
  • OBJECTIVE: This study aims to evaluate the effect of incubation time (1 vs. 3 h), MAL concentration (160 mg/g vs. 80 mg/g) and lesion preparation in the setting of MAL-PDT for treatment of actinic keratosis (AK).
  • MAIN OUTCOME: Complete lesion response rates 3 and 12 months after last treatment.
  • RESULTS: For lesions on the face/scalp, lesion complete response rates were 78% for thin AK and 74% for moderately thick AK lesions after 1 h vs. 96% and 87% after 3 h incubation with MAL 160 mg/g.
  • Lesion recurrence rates at 12 months after two treatments were similar [19% (3 of 16) with 1 h vs. 17% (3 of 18) with 3 h 160 mg/kg MAL-PDT] and lower than for 80 mg/g MAL-PDT (44-45%).
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Keratosis, Actinic / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415804.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cosmetics; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


62. Martínez A, Brethauer U, Borlando J, Spencer ML, Rojas IG: Epithelial expression of p53, mdm-2 and p21 in normal lip and actinic cheilitis. Oral Oncol; 2008 Sep;44(9):878-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial expression of p53, mdm-2 and p21 in normal lip and actinic cheilitis.
  • To assess if the p53-regulated proteins murine-double-minute (mdm)-2 and p21 are altered during early lip carcinogenesis, biopsies from normal lip (n=16) and the premalignant lip lesion, actinic cheilitis (AC) (n=26) were processed for the immunohistochemical detection of p53, p21 and mdm-2 in serial co-localized sections.

  • Genetic Alliance. consumer health - Actinic Cheilitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18234540.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


63. Gebauer K, Shumack S, Cowen PS: Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. Br J Dermatol; 2009 Oct;161(4):897-903
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
  • BACKGROUND: Clinical studies in cutaneous conditions other than actinic keratosis (AK) have revealed that the safety and efficacy profile of imiquimod is influenced by dosing frequency.
  • Complete clearance was achieved in 0%, 3.2%, 6.9%, 3.3% and 6.7% of subjects, and partial clearance (> or = 75% lesion reduction) in 0%, 22.6%, 24.1%, 20.0% and 36.7% of subjects for the placebo and imiquimod 2, 3, 5 or 7 times per week regimens, respectively.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Hand Dermatoses / drug therapy. Keratosis, Actinic / drug therapy. Precancerous Conditions / drug therapy

  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19545297.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


64. Jones M Pd Fiaca Faca: Dermatological effects from years in the sun: compounding opportunities. Int J Pharm Compd; 2006 Sep-Oct;10(5):336-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common sun-induced pre-cancerous lesion is solar keratosis, or actinic keratosis.
  • Unless detected and treated, actinic keratosis can progress to skin cancer.
  • The best treatment option depends on the type and location of lesion, the stage of the lesion, and the needs of the individual patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23974311.001).
  • [ISSN] 1092-4221
  • [Journal-full-title] International journal of pharmaceutical compounding
  • [ISO-abbreviation] Int J Pharm Compd
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Sezer E, Böer A, Falk T: Identification of human papilloma virus type 6 in psoriasiform keratosis. Am J Dermatopathol; 2010 Jul;32(5):492-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Psoriasiform keratosis is a recently reported unique clinicopathological entity characterized by the appearance of a solitary lesion mimicking seborrheic keratosis, actinic keratosis, or squamous cell carcinoma and histopathologic features closely resembling psoriasis.
  • We report a 74-year-old woman presenting with a solitary, scaly lesion on the dorsum of the left arm of several months duration and histopathologic findings of psoriasiform acanthosis of the epidermis with thinning of the suprapapillary plates and intraepidermal spongiform neutrophilic pustules, consistent with a diagnosis of psoriasiform keratosis.

  • MedlinePlus Health Information. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20442638.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


66. Calzavara-Pinton PG, Venturini M, Sala R, Capezzera R, Parrinello G, Specchia C, Zane C: Methylaminolaevulinate-based photodynamic therapy of Bowen's disease and squamous cell carcinoma. Br J Dermatol; 2008 Jul;159(1):137-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Photodynamic therapy (PDT) with methylaminolaevulinate (MAL) is an approved noninvasive treatment option for actinic keratosis and Bowen's disease (BD), two precursors of invasive squamous cell carcinoma (SCC).
  • Clinical thickness, atypia and lesion depth were significant predictors of the response at 3 months when using a univariate analysis (P < 0.001).


67. Berman B, Amini S, Valins W, Block S: Pharmacotherapy of actinic keratosis. Expert Opin Pharmacother; 2009 Dec;10(18):3015-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacotherapy of actinic keratosis.
  • Actinic keratosis (AK) represents the initial intraepidermal manifestation of abnormal keratinocyte proliferation with the potential of progression to squamous cell carcinoma (SCC).
  • When in limited numbers, clinically visible AKs are treated individually with ablative and/or surgical procedures (lesion-directed treatment), while multiple and sublinical AKs are treated with field-directed therapies that use ablative, nonablating and other topically applied treatment modalities.
  • Lesion-directed treatment modalities include cryotherapy, surgery and electrodessication with or without curettage.
  • [MeSH-major] Keratosis, Actinic / drug therapy

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19925043.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 179
  •  go-up   go-down


68. Tomas D, Kruslin B, Cupic H, Stanimirovic A, Bosnjak B, Lovricevic I, Belicza M: Correlation between Bcl-2 and Bax in atrophic and hypertrophic type of actinic keratosis. J Eur Acad Dermatol Venereol; 2006 Jan;20(1):51-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between Bcl-2 and Bax in atrophic and hypertrophic type of actinic keratosis.
  • BACKGROUND: Recent investigations consider actinic keratosis (AK) as an earliest visible pattern of squamous cell carcinoma (SCC).
  • Statistical analysis did not show any correlation between patient's sex and age, localization and size of the lesion with expression of investigated oncoproteins (anova, P > 0.05).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405608.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein
  •  go-up   go-down


69. Rajaram N, Reichenberg JS, Migden MR, Nguyen TH, Tunnell JW: Pilot clinical study for quantitative spectral diagnosis of non-melanoma skin cancer. Lasers Surg Med; 2010 Dec;42(10):716-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • White light reflectance and laser-induced fluorescence spectra (wavelength range = 350-700 nm) were collected from each suspected lesion and adjacent clinically normal skin using a custom-built, optical fiber-based clinical instrument.
  • RESULTS: Scattering from cancerous lesions was significantly lower than normal skin for every lesion group, whereas absorption parameters were significantly higher.
  • Similarly, the instrument classified actinic keratoses and squamous cell carcinomas with a sensitivity of 100% and specificity of 50%.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Wiley-Liss, Inc.
  • [Cites] Cancer. 2003 Apr 1;97(7):1681-92 [12655525.001]
  • [Cites] Lasers Surg Med. 2002;31(5):367-73 [12430156.001]
  • [Cites] Appl Opt. 2004 May 1;43(13):2643-50 [15130003.001]
  • [Cites] Opt Lett. 2004 May 15;29(10):1087-9 [15181994.001]
  • [Cites] Clin Dermatol. 2004 May-Jun;22(3):189-96 [15262304.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Photochem Photobiol. 1992 Apr;55(4):515-22 [1620728.001]
  • [Cites] Stat Med. 1997 Dec 30;16(24):2813-27 [9483716.001]
  • [Cites] J Biomed Opt. 2005 Mar-Apr;10(2):024032 [15910105.001]
  • [Cites] J Biomed Opt. 2005 Nov-Dec;10(6):064020 [16409085.001]
  • [Cites] Br J Dermatol. 2006 Jul;155(1):100-3 [16792759.001]
  • [Cites] J Gen Intern Med. 2006 Jul;21(7):678-82 [16808765.001]
  • [Cites] J Biomed Opt. 2006 Nov-Dec;11(6):064026 [17212549.001]
  • [Cites] Australas J Dermatol. 2007 May;48(2):77-82 [17535192.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034004 [17614712.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034027 [17614735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19494-9 [18042710.001]
  • [Cites] J Biomed Opt. 2008 Jan-Feb;13(1):014017 [18315375.001]
  • [Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024012 [18465975.001]
  • [Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024013 [18465976.001]
  • [Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024017 [18465980.001]
  • [Cites] J Biomed Opt. 2008 May-Jun;13(3):034015 [18601560.001]
  • [Cites] Lasers Surg Med. 2008 Sep;40(7):461-7 [18727020.001]
  • [Cites] Opt Express. 2008 Sep 15;16(19):14961-78 [18795033.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):050501 [19021373.001]
  • [Cites] Skin Res Technol. 2008 Aug;14(3):364-9 [19159385.001]
  • [Cites] Appl Opt. 2010 Jan 10;49(2):142-52 [20062500.001]
  • [Cites] Lasers Surg Med. 2010 Sep;42(7):680-8 [20740619.001]
  • [Cites] CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 [20610543.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):4-7 [10607349.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):8-10 [10607350.001]
  • [Cites] Phys Med Biol. 2000 Mar;45(3):735-51 [10730968.001]
  • [Cites] South Med J. 2000 Jul;93(7):650-5 [10923948.001]
  • [Cites] Neoplasia. 2000 Jan-Apr;2(1-2):89-117 [10933071.001]
  • [Cites] Melanoma Res. 2000 Dec;10(6):563-70 [11198478.001]
  • [Cites] Photochem Photobiol. 2001 Feb;73(2):178-83 [11272732.001]
  • [Cites] Photochem Photobiol. 2001 Jun;73(6):636-41 [11421069.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):682-7 [11830520.001]
  • [Cites] Lancet Oncol. 2002 Mar;3(3):159-65 [11902502.001]
  • [Cites] Am J Obstet Gynecol. 2002 Mar;186(3):374-82 [11904594.001]
  • [Cites] IEEE Trans Biomed Eng. 2003 Nov;50(11):1233-42 [14619993.001]
  • (PMID = 21246575.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA132032-03; United States / NCI NIH HHS / CA / R01 CA132032; United States / NCI NIH HHS / CA / R01 CA132032-03
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS244012; NLM/ PMC3059518
  •  go-up   go-down


70. Dang C, Gottschling M, Roewert J, Forschner T, Stockfleth E, Nindl I: Tenascin-C patterns and splice variants in actinic keratosis and cutaneous squamous cell carcinoma. Br J Dermatol; 2006 Oct;155(4):763-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tenascin-C patterns and splice variants in actinic keratosis and cutaneous squamous cell carcinoma.
  • The mRNA expression and protein level of Tn-C including its various isoforms have not been investigated comprehensively so far in cutaneous squamous cell carcinoma (SCC) and the precursor lesion actinic keratosis (AK).

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965426.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Tenascin
  •  go-up   go-down


71. Zide MF: Actinic keratosis: from the skin to the lip. J Oral Maxillofac Surg; 2008 Jun;66(6):1162-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratosis: from the skin to the lip.
  • PURPOSE: Actinic keratoses are commonly the result of intense sun damage to the skin and lips of susceptible patients.
  • PATIENTS AND METHODS: The first section discusses the options chosen for patients who were referred to the Facial Lesion Clinic in a county hospital for precancerous or cancerous facial lesions; the second section reviews ramifications for precancerous sun-damaged lips with clinical leukoplakia.

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486781.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


72. Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor AC, Stocker M, Ortland C, Brunnert M, Szeimies RM: Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol; 2009 May;160(5):1066-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Photodynamic therapy (PDT) is increasingly used for treatment of actinic keratoses (AKs) but is a cumbersome procedure.
  • Efficacy rates on a lesion basis were 82% (AK 03) and 89% (AK 04) for PDT, 77% for cryosurgery and 19% (AK 03) and 29% (AK 04) for placebo-PDT.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Keratosis, Actinic / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222455.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dosage Forms; 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


73. Kaufmann R, Spelman L, Weightman W, Reifenberger J, Szeimies RM, Verhaeghe E, Kerrouche N, Sorba V, Villemagne H, Rhodes LE: Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol; 2008 May;158(5):994-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities.
  • BACKGROUND: Methyl aminolaevulinate-photodynamic therapy (MAL-PDT) is an effective treatment in facial/scalp actinic keratosis (AK).
  • The primary efficacy variable was the lesion response at week 24.
  • Both treatments provided a high mean percentage reduction in lesion count at week 24 with significantly higher efficacy for cryotherapy: 78% for MAL-PDT and 88% for cryotherapy (P=0.002, per protocol population).


74. Ming M, Han W, Maddox J, Soltani K, Shea CR, Freeman DM, He YY: UVB-induced ERK/AKT-dependent PTEN suppression promotes survival of epidermal keratinocytes. Oncogene; 2010 Jan 28;29(4):492-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As compared with normal skin, PTEN levels are reduced in human actinic keratosis, a precancerous skin lesion caused by solar UV.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Phys Physiol Meas. 1991 Nov;12(4):311-25 [1778030.001]
  • [Cites] Phys Med Biol. 1991 Mar;36(3):299-328 [1645473.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):356-62 [9090379.001]
  • [Cites] Nat Genet. 1997 May;16(1):64-7 [9140396.001]
  • [Cites] Nat Genet. 1997 Aug;16(4):333-4 [9241266.001]
  • [Cites] Genes Dev. 1998 Feb 15;12(4):502-13 [9472019.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13375-8 [9593664.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jun;22(2):152-6 [9598803.001]
  • [Cites] Curr Biol. 1998 Oct 22;8(21):1169-78 [9799734.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2006-11 [15598755.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1521-31 [16247443.001]
  • [Cites] Oncogene. 2006 Jun 22;25(26):3680-8 [16682958.001]
  • [Cites] Neoplasma. 2006;53(4):328-32 [16830061.001]
  • [Cites] Cell. 2006 Nov 3;127(3):481-93 [17081972.001]
  • [Cites] Cell Death Differ. 2007 Feb;14(2):218-29 [16676006.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10343-50 [17974977.001]
  • [Cites] Photochem Photobiol. 2008 Jan-Feb;84(1):69-74 [18173704.001]
  • [Cites] Adv Exp Med Biol. 2008;624:283-95 [18348464.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S129-32 [18410798.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3752-8 [18483258.001]
  • [Cites] J Invest Dermatol. 2000 Feb;114(2):277-80 [10651986.001]
  • [Cites] J Biol Chem. 2000 Aug 4;275(31):23919-26 [10787418.001]
  • [Cites] J Invest Dermatol. 2000 Sep;115(3):427-34 [10951279.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):493-7 [11179477.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):993-8 [11035045.001]
  • [Cites] Development. 2002 Sep;129(17):4159-70 [12163417.001]
  • [Cites] Sci STKE. 2003 Jan 28;2003(167):RE2 [12554854.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):674-81 [12566313.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):318-27 [12569555.001]
  • [Cites] J Biol Chem. 2003 Aug 15;278(33):30652-60 [12788938.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):23-35 [14681688.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1725-30 [14747659.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):533-43 [15009741.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Sep;71(9):3363-6 [4530308.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Aug;67(2):373-8 [2839537.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5545-9 [7777546.001]
  • (PMID = 19881543.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA014599-34; United States / NCRR NIH HHS / RR / UL1 RR024999; United States / NIEHS NIH HHS / ES / R01 ES016936-01A2; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / CA014599-33; United States / NCI NIH HHS / CA / P30 CA014599-330014; United States / NCRR NIH HHS / RR / RR024999-03; United States / NCRR NIH HHS / RR / RR024999-01; United States / NCI NIH HHS / CA / P30 CA014599-34; United States / NCRR NIH HHS / RR / UL1 RR024999-03; United States / NCI NIH HHS / CA / CA014599-340014; United States / NIEHS NIH HHS / ES / R01 ES016936; United States / NCI NIH HHS / CA / CA014599-330014; United States / NCRR NIH HHS / RR / UL1 RR024999-02; United States / NCRR NIH HHS / RR / UL1 RR024999-01; United States / NCI NIH HHS / CA / CA014599-32; United States / NCI NIH HHS / CA / P30 CA014599-33; United States / NCI NIH HHS / CA / P30 CA014599-340014; United States / NIEHS NIH HHS / ES / ES016936-01A2; United States / NCRR NIH HHS / RR / UL1RR024999; United States / NCI NIH HHS / CA / P30 CA014599-32
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.48 / Pten protein, mouse; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ NIHMS147984; NLM/ PMC2813408
  •  go-up   go-down


76. Tierney EP, Eide MJ, Jacobsen G, Ozog D: Photodynamic therapy for actinic keratoses: survey of patient perceptions of treatment satisfaction and outcomes. J Cosmet Laser Ther; 2008 Jun;10(2):81-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for actinic keratoses: survey of patient perceptions of treatment satisfaction and outcomes.
  • BACKGROUND: While there are many available treatments for actinic keratoses (AKs), patient-preferred treatment options remain undefined.
  • CONCLUSION: While the effectiveness of lesion clearance with PDT for AKs has been well proven in the literature, this is the first study to evaluate patient perception of the effectiveness, side-effect profile and benefits of PDT relative to several standard treatment approaches for AKs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18569260.001).
  • [ISSN] 1476-4180
  • [Journal-full-title] Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
  • [ISO-abbreviation] J Cosmet Laser Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


77. Ulrich C, Bichel J, Euvrard S, Guidi B, Proby CM, van de Kerkhof PC, Amerio P, Rønnevig J, Slade HB, Stockfleth E: Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol; 2007 Dec;157 Suppl 2:25-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients.
  • OBJECTIVE: In this study the safety and efficacy of imiquimod 5% cream for the treatments of actinic keratoses in kidney, heart and liver transplant recipients is evaluated.
  • BACKGROUND: Growing populations of organ transplant recipients face increased risk of developing actinic keratosis (AK) and skin cancer secondary to continuous systemic immunosuppressive therapy.
  • Dosing continued for 16 weeks regardless of lesion clearance.
  • CONCLUSIONS: Imiquimod appears to be a safe alternative for the treatment of multiple actinic keratoses in patients with solid organ transplants.


78. Pariser D, Loss R, Jarratt M, Abramovits W, Spencer J, Geronemus R, Bailin P, Bruce S: Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: A randomized, double-blind, placebo-controlled study. J Am Acad Dermatol; 2008 Oct;59(4):569-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: A randomized, double-blind, placebo-controlled study.
  • BACKGROUND: The use of light-emitting diode light offers practical advantages in photodynamic therapy (PDT) with topical methyl-aminolevulinate (MAL) for management of actinic keratoses (AK).
  • Complete lesion and patient (all lesions showing complete response) response rates were evaluated 3 months after last treatment.
  • RESULTS: MAL PDT was superior (P<.0001) to vehicle PDT with respect to lesion complete response (86.2% vs 52.2%, odds ratio 6.9 [95% confidence interval 4.7-10.3]) and patient complete response (59.2% vs 14.9%, odds ratio 13.2 [95% confidence interval 4.1-43.1]).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707799.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


79. Walsh SN, Hurt MA, Santa Cruz DJ: Psoriasiform keratosis. Am J Dermatopathol; 2007 Apr;29(2):137-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common diagnoses, clinically, were seborrheic keratosis, followed by basal cell carcinoma, Bowen's disease, actinic (solar) keratosis, and squamous cell carcinoma, among others.
  • It is unclear whether a psoriasiform keratosis is a rudimentary manifestation of psoriasis or a lesion sui generis.

  • MedlinePlus Health Information. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414434.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Szeimies RM, Radny P, Sebastian M, Borrosch F, Dirschka T, Krähn-Senftleben G, Reich K, Pabst G, Voss D, Foguet M, Gahlmann R, Lübbert H, Reinhold U: Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol; 2010 Aug;163(2):386-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study.
  • BACKGROUND: Photodynamic therapy (PDT) with 5-aminolaevulinic acid (ALA) provides a therapeutic option for the treatment of actinic keratosis (AK).
  • RESULTS: PDT with BF-200 ALA was superior to placebo PDT with respect to patient complete clearance rate (per-protocol group: 64% vs. 11%; P < 0.0001) and lesion complete clearance rate (per-protocol group: 81% vs. 22%) after the last PDT treatment.
  • Statistically significant differences in the patient and lesion complete clearance rates and adverse effect profiles were observed for the two light sources, Aktilite CL128 and PhotoDyn 750, at both time points of assessment.
  • The patient and lesion complete clearance rates after illumination with the Aktilite CL128 were 96% and 99%, respectively.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Keratosis, Actinic / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2010 Aug;163(2):236-7 [20666768.001]
  • (PMID = 20518784.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


81. Werschler WP: Considerations for use of Fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients. J Clin Aesthet Dermatol; 2008 Jul;1(2):22-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Considerations for use of Fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients.
  • Actinic keratosis (AK), the initial lesion in a disease continuum that may progress to squamous cell carcinoma, often begins with ultraviolet B light-induced photo damage and increases in prevalence with age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21103319.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2989823
  •  go-up   go-down


82. Munday JS, Hanlon EM, Howe L, Squires RA, French AF: Feline cutaneous viral papilloma associated with human papillomavirus type 9. Vet Pathol; 2007 Nov;44(6):924-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The skin surrounding the mass was nonpigmented, and actinic keratosis had been diagnosed in this area 3 years previously.
  • Polymerase chain reaction amplified papillomaviral deoxyribonucleic acid from formalin-fixed samples of the lesion.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039907.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Smith SR, Morhenn VB, Piacquadio DJ: Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol; 2006 Feb;5(2):156-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp.
  • Actinic keratoses (AKs) are a common precancerous condition and are said to account for 14% of visits to dermatologists in the US each year.
  • The diclofenac gel and 5-fluorouracil cream each demonstrated substantial efficacy in the number of lesions cleared and the proportion of patients with significant lesion clearing.

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485883.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antimetabolites, Antineoplastic; 0 / Gels; 144O8QL0L1 / Diclofenac; U3P01618RT / Fluorouracil
  •  go-up   go-down


84. Morton C, Campbell S, Gupta G, Keohane S, Lear J, Zaki I, Walton S, Kerrouche N, Thomas G, Soto P, AKtion Investigators: Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol; 2006 Nov;155(5):1029-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study.
  • BACKGROUND: Actinic keratosis (AK), the most common premalignant skin condition, can represent a management challenge.
  • OBJECTIVES: The primary objective was to compare the lesion response and subject preference for topical methyl aminolaevulinate (MAL)-photodynamic therapy (PDT) vs. cryotherapy for the treatment of AK.
  • The primary assessments were the subject's overall preference and lesion response at week 24.
  • Secondary assessments included lesion response at week 12, cosmetic outcome, subject and investigator cosmetic outcome preference at week 24, and investigator overall preference at week 24.
  • At week 12, treatment with MAL-PDT resulted in a significantly larger rate of cured lesions relative to cryotherapy (percentage lesion reduction from baseline: 86.9% vs. 76.2%; P < 0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034536.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


85. Aractingi S, Kanitakis J, Euvrard S, Le Danff C, Peguillet I, Khosrotehrani K, Lantz O, Carosella ED: Skin carcinoma arising from donor cells in a kidney transplant recipient. Cancer Res; 2005 Mar 1;65(5):1755-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Male cells were detected in 5/15 squamous cell carcinomas and Bowen disease (range 4-180 copies), 3/5 basal cell carcinomas (91-645), 6/11 actinic keratosis (7-102), 2/4 keratoacanthoma (22-41), and 2/5 benign cutaneous lesions (14-55).
  • In this lesion, immuno-FISH showed the presence of XY cytokeratin-positive cells indicating that the tumor nests contained male keratinocytes.


86. Ahlgrimm-Siess V, Hofmann-Wellenhof R, Cao T, Oliviero M, Scope A, Rabinovitz HS: Reflectance confocal microscopy in the daily practice. Semin Cutan Med Surg; 2009 Sep;28(3):180-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three flat pigmented skin lesions with dermoscopic signs of regression showed distinct RCM features that allowed their correct classification as pigmented basal cell carcinoma, pigmented actinic keratosis, and melanoma on sun-damaged skin.
  • A flat nonpigmented skin lesion on the face, which did not show distinct clinical or dermoscopic features, was correctly diagnosed as basal cell carcinoma based on RCM findings.
  • In addition, the response of a pigmented actinic keratosis and a melanoma in situ on sun-damaged skin to noninvasive topical treatment was monitored using RCM.

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19782942.001).
  • [ISSN] 1558-0768
  • [Journal-full-title] Seminars in cutaneous medicine and surgery
  • [ISO-abbreviation] Semin Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Fariba I, Ali A, Hossein SA, Atefeh S, Atarzadeh Behbahan SA: Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study. Indian J Dermatol Venereol Leprol; 2006 Sep-Oct;72(5):346-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study.
  • BACKGROUND: Actinic keratoses (AKs) are premalignant skin lesions caused by excessive sun exposure.
  • RESULTS: There was a reduction in the lesion size in 64.7% of diclofenac-treated lesions and 34.3% of control lesions during the three-month course of treatment.
  • CONCLUSION: Considering the malignant potential of actinic keratoses and the importance of clearing them to prevent their transformation to squamous cell carcinoma, the efficacy of diclofenac gel seen in our study seems to be low.
  • This treatment may be useful for patients who do not tolerate other, more effective kinds of treatment for actinic keratoses.

  • Hazardous Substances Data Bank. DICLOFENAC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050927.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Gels; 144O8QL0L1 / Diclofenac
  •  go-up   go-down


88. Alvarenga MP, Thuler LC, Neto SP, Vasconcelos CC, Camargo SG, Alvarenga MP, Papais-Alvarenga RM: The clinical course of idiopathic acute transverse myelitis in patients from Rio de Janeiro. J Neurol; 2010 Jun;257(6):992-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 70 cases of acute myelopathies, the idiopathic form was identified in 41 following exclusion of the cases associated with systemic lupus erythematosus (n = 1), Sjogren's syndrome (n = 1), herpes zoster (n = 1), cytomegalovirus in an HIV-positive patient (n = 1), Schistosoma mansoni (n = 1), actinic myelitis (n = 1), infectious myelitis of unknown etiology (n = 2) and those that, following the first attack of myelitis, converted to NMO (n = 19) or to clinically defined MS (n = 2).
  • Serial spine MRI confirmed spinal cord inflammation in 92.0% of cases and extensive spinal cord lesion was identified in 61.0%.

  • Genetic Alliance. consumer health - Myelitis.
  • Genetic Alliance. consumer health - Transverse myelitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurologist. 2005 Jan;11(1):2-18 [15631640.001]
  • [Cites] Arch Neurol. 1993 May;50(5):532-5 [8489410.001]
  • [Cites] Neurology. 2007 Mar 27;68(13):1076-7 [17287449.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):566-9 [16453327.001]
  • [Cites] Mult Scler. 2005 Aug;11(4):373-7 [16042216.001]
  • [Cites] J Exp Med. 2005 Aug 15;202(4):473-7 [16087714.001]
  • [Cites] Arch Neurol. 1973 Apr;28(4):252-7 [4688431.001]
  • [Cites] Intern Med. 2005 Jun;44(6):560-6 [16020880.001]
  • [Cites] Neurology. 2002 Aug 27;59(4):499-505 [12236201.001]
  • [Cites] Front Biosci. 2004 May 01;9:1483-99 [14977560.001]
  • [Cites] Arq Neuropsiquiatr. 2001 Mar;59(1):89-91 [11299438.001]
  • [Cites] Curr Opin Neurol. 2002 Jun;15(3):339-47 [12045735.001]
  • [Cites] Ann Neurol. 2001 Jul;50(1):121-7 [11456302.001]
  • [Cites] J Neurol. 2004 Jan;251(1):47-52 [14999489.001]
  • [Cites] Mult Scler. 2008 May;14(4):440-5 [18208892.001]
  • [Cites] J Neurol Sci. 1996 Jun;138(1-2):150-6 [8791253.001]
  • [Cites] Neurol India. 1999 Dec;47(4):294-9 [10625902.001]
  • [Cites] Neurology. 2005 Dec 27;65(12):1950-3 [16380618.001]
  • [Cites] Eur J Neurol. 2006 Aug;13(8):862-8 [16879297.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1107-14 [10496275.001]
  • [Cites] Neurology. 1981 Aug;31(8):966-71 [7196523.001]
  • [Cites] Brain. 1997 Jul;120 ( Pt 7):1115-22 [9236624.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Oct;73(4):429-35 [12235313.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Apr;60(4):382-7 [8774400.001]
  • [Cites] Semin Neurol. 2002 Jun;22(2):105-22 [12524556.001]
  • [Cites] Acta Neurol Scand. 1990 May;81(5):431-5 [2375246.001]
  • [Cites] Arch Neurol. 2003 Sep;60(9):1290-4 [12975297.001]
  • [Cites] Neurology. 1983 Nov;33(11):1444-52 [6685237.001]
  • [Cites] Neurology. 1992 Jan;42(1):250-2 [1285728.001]
  • [Cites] Acta Neurol Scand. 2007 Jun;115(6):371-6 [17511844.001]
  • [Cites] J Neurol. 2003 Dec;250(12):1447-52 [14673577.001]
  • [Cites] Lancet. 2004 Dec 11-17;364(9451):2106-12 [15589308.001]
  • [Cites] Eur J Neurol. 2008 Apr;15(4):398-405 [18312402.001]
  • (PMID = 20127351.001).
  • [ISSN] 1432-1459
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Aquaporin 4; 0 / Autoantibodies
  •  go-up   go-down


89. Zaravinos A, Kanellou P, Spandidos DA: Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers. Br J Dermatol; 2010 Feb 1;162(2):325-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers.
  • BACKGROUND: Actinic keratosis (AK) is a well-established precancerous skin lesion that has the potential to progress to squamous cell carcinoma (SCC).
  • [MeSH-major] Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / virology. DNA, Viral / isolation & purification. Genes, ras / genetics. Keratosis, Actinic / virology. Skin Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19849697.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


90. Bruscino N, Rossi R, Dindelli M, Ghersetich I, Lotti T: Therapeutic Hotline: Facial skin rejuvenation in a patient treated with photodynamic therapy for actinic keratosis. Dermatol Ther; 2010 Jan-Feb;23(1):86-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic Hotline: Facial skin rejuvenation in a patient treated with photodynamic therapy for actinic keratosis.
  • The aim of the most used treatments of actinic keratoses (AKs) is to avoid the conversion into invasive squamous cell carcinoma through the destruction of the lesion; a lot of therapeutic modalities (imiquimod, 5-fluorouracil, electrosurgery with curettage, cryosurgery) are effective and safe in this field, but not many can do it with excellent cosmetic results like treatment with photodynamic therapy (PDT).
  • This kind of therapy has removed not only the lesion but also the photoaging manifestations like the wrinkles and the ugly lines, leaving a smooth skin, as we have proved with 3D-profilometry technique.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Keratosis, Actinic / radiotherapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Rejuvenation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20136912.001).
  • [ISSN] 1529-8019
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


91. Fayter D, Corbett M, Heirs M, Fox D, Eastwood A: A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin. Health Technol Assess; 2010 Jul;14(37):1-288
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For actinic keratosis (AK), the only clear evidence of effectiveness was that PDT appeared to be superior to placebo.
  • For basal cell carcinoma (BCC), PDT may result in similar lesion response rates to surgery or cryotherapy but with better cosmetic outcomes.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • PubMed Health. PubMed Health .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20663420.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  •  go-up   go-down


92. da Silva TA, Coelho G, Lorenzetti Bocca A, Figueiredo Cavalcante Neto F: Expression of apoptotic, cell proliferation regulatory, and structural proteins in actinic keratosis and their association with dermal elastosis. J Cutan Pathol; 2007 Apr;34(4):315-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of apoptotic, cell proliferation regulatory, and structural proteins in actinic keratosis and their association with dermal elastosis.
  • BACKGROUND: Actinic keratosis (AK) is a premalignant lesion caused by ultraviolet (UV) radiation and characterized by epithelial and connective tissue alterations.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17381802.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


93. Dissemond J, Grabbe S: [Actinic keratosis]. MMW Fortschr Med; 2006 Jun 15;148(24):38-9, 41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Actinic keratosis].
  • Actinic keratosis is a precancerous lesion that is commonly seen in the elderly patient and requires treatment.
  • The diagnosis is usually based on the clinical appearance of the lesion.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850807.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Interferon Inducers; 0 / Ointments; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 0
  •  go-up   go-down


94. Han A, Penrose C, Goldsmith A, Marmur ES: Case-based considerations in the treatment of actinic keratoses: utilizing combination or sequential therapy with 5-fluorouracil cream and destructive treatments. J Drugs Dermatol; 2010 Jul;9(7):864-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case-based considerations in the treatment of actinic keratoses: utilizing combination or sequential therapy with 5-fluorouracil cream and destructive treatments.
  • Actinic keratoses are premalignant lesions that increase in frequency with each decade of life and have the potential to progress to squamous cell carcinoma.
  • Therapeutic options for these conditions are abundant and range from topical field-directed therapies to destructive, lesion-directed procedures.
  • The following case-based review represents typical situations where multiple treatments were combined to manage actinic keratosis, squamous cell carcinoma and basal cell carcinoma in patients over an extended treatment period.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Fluorouracil / administration & dosage. Keratosis, Actinic / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677546.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


95. Ulrich M, Maltusch A, Röwert-Huber J, González S, Sterry W, Stockfleth E, Astner S: Actinic keratoses: non-invasive diagnosis for field cancerisation. Br J Dermatol; 2007 May;156 Suppl 3:13-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses: non-invasive diagnosis for field cancerisation.
  • BACKGROUND: Actinic keratoses (AKs) are among the most common cutaneous malignancies and have previously been classified as in situ squamous cell carcinoma (SCC) with reported progression rates of up to 20% over 10 years.
  • PATIENTS/METHODS: Forty four Caucasians (SPT I-III) with a minimum of one actinic keratosis (AK) lesion were included in this study.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488401.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


96. Berman B, Villa AM, Ramirez CC: Mechanisms of action of new treatment modalities for actinic keratosis. J Drugs Dermatol; 2006 Feb;5(2):167-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of action of new treatment modalities for actinic keratosis.
  • Actinic keratosis (AK) constitutes the initial lesion in a disease continuum that can progress to invasive squamous cell carcinoma (SCC).
  • In this article, we describe the mechanisms of action, tolerability, and efficacy of the most frequently used chemopreventative, chemotherapeutic, destructive, and novel immunologic methods for the control and treatment of actinic keratoses.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485885.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antimetabolites; 0 / Antineoplastic Agents; 0 / Teratogens; 144O8QL0L1 / Diclofenac; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 46
  •  go-up   go-down


97. Brodsky J: Management of benign skin lesions commonly affecting the face: actinic keratosis, seborrheic keratosis, and rosacea. Curr Opin Otolaryngol Head Neck Surg; 2009 Aug;17(4):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of benign skin lesions commonly affecting the face: actinic keratosis, seborrheic keratosis, and rosacea.
  • Advances in the understanding and management of three of the more common benign skin lesions affecting the face will be addressed in this review, with a particular emphasis on the most current therapeutic options for each lesion.
  • RECENT FINDINGS: Actinic keratosis can now be treated with photodynamic therapy or with many topical agents, as alternatives to traditional surgical techniques.
  • Seborrheic keratosis, as well as actinic keratosis and rosacea, are now often treated with laser therapy.
  • [MeSH-major] Facial Dermatoses / therapy. Keratosis, Actinic / therapy. Keratosis, Seborrheic / therapy. Rosacea / therapy


98. Pock L, Drlík L, Hercogová J: Dermatoscopy of pigmented actinic keratosis--a striking similarity to lentigo maligna. Int J Dermatol; 2007 Apr;46(4):414-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatoscopy of pigmented actinic keratosis--a striking similarity to lentigo maligna.
  • BACKGROUND: Pigmented actinic keratosis (PAK) resembles lentigo maligna (LM) clinically and histopathologically in some cases.
  • OBJECTIVES: To describe the dermatoscopical characteristics of this uncommon variant of actinic keratosis and evaluate whether these characteristics show common features with LM.
  • OBSERVATIONS: We had the opportunity to examine a 78-year-old woman who presented with a PAK lesion on her face dermatoscopically and histopathologically.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442088.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Szeimies RM, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor AC, Stocker M, Ortland C, Brunnert M, Hauschild A: Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. Br J Dermatol; 2010 Feb 1;162(2):410-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Photodynamic therapy with a self-adhesive 5-aminolaevulinic acid (5-ALA) patch shows high efficacy rates in the treatment of mild to moderate actinic keratosis (AK) in short term trials.
  • Patients had to show at least one successfully treated AK lesion after initial therapy.
  • On a lesion basis, efficacy rates were 63% and 79% for PDT, 63% for cryosurgery and 9% and 25% for placebo-PDT.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Keratosis, Actinic / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804593.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


100. Maury G, Girard C, Michot C, Guillot B, Dereure O: [Multiple Bowen disease of the lower limbs in elderly women: a rare clinical subset involving therapeutic difficulties]. Ann Dermatol Venereol; 2009 Jun-Jul;136(6-7):508-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cutaneous Bowen's disease (CBD) is a form of intraepithelial squamous cell carcinoma that usually presents as a solitary lesion.
  • OBSERVATIONS: Four women aged over 70 years presented with multiple CBD limited to the lower limbs associated with squamous cell and superficial basal cell carcinomas along with actinic keratosis.
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / complications. Female. Humans. Keratosis, Actinic / complications. Photochemotherapy. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19560611.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down






Advertisement